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The functionally important regions of signal proteins participating in their speciﬁc interaction and responsible for transduction of
hormonalsignalintocellarerathershortinlength,having,asarule,8to20aminoacidresidues.Syntheticpeptidescorresponding
to these regions are able to mimic the activated form of full-size signal protein and to trigger signaling cascades in the absence of
hormonal stimulus. They modulate protein-protein interaction and inﬂuence the activity of signal proteins followed by changes
in their regulatory and catalytic sites. The present review is devoted to the achievements and perspectives of the study of signal
protein-derived peptides and to their application as selective and eﬀective regulators of hormonal signaling systems in vitro and in
vivo. Attention is focused on the structure, biological activity, and molecular mechanisms of action of peptides, derivatives of the
receptors, G protein α subunits, and the enzymes generating second messengers.
1.Introduction
The transduction of signals generated by hormones and
hormone-like substances of diﬀerent nature to intracellular
eﬀector proteins controlling the fundamental cellular pro-
cesses requires coordinated activity of many signal proteins,
components of a wide spectrum of G protein-coupled and
G protein-independent signaling systems, and has several
steps in common. The ﬁrst step is the recognition and
speciﬁc binding of ligands with extracellular domains of
sensors represented by some families of transmembrane
proteins, such as the G protein-coupled receptors (GPCRs)
seven times penetrating the plasma membrane, the tyrosine
kinasereceptorshavingasingletransmembraneregion(TM)
and intracellular domain possessing the intrinsic tyrosine
kinaseactivity,thenatriureticpeptidereceptorsincludingthe
membrane-bound guanylyl cyclases, and natriuretic peptide
clearance receptor (NPR-C) lacking cyclase activity. The
ligand binding is responsible for alteration of conformation
of the extracellular regions of receptor and, in the case
of GPCRs, for changes of the three-dimensional structure
of receptor transmembrane channel (TMC) participating
in formation of the ligand-binding site, which starts to
transfer the external signal across the plasma membrane
and triggers intracellular signaling cascade [1–3]. In the
case of G protein-coupled signaling systems the second
step of signal transduction is the interaction of intracellular
regionsofligand-activatedreceptorwithαsubunitand/orβγ
dimer of heterotrimeric G protein in inactive, GDP-bound,
state, which induces the GDP/CTP exchange in guanine
nucleotide-binding site of Gα subunit and the dissociation
of GTP-bound Gα subunit from Gβγ dimer, and the third
step is the interaction of GTP-bound Gα subunit or free
Gβγ dimeric complex with the enzymes, adenylyl cyclase
(AC) and phospholipase C (PLC), generating the second
messengers, or with the ionic channels, which signiﬁcantly
amplify the initial signal [4–6]. In the activated state the Gα
subunit possesses intrinsic GTPase activity and hydrolyses
the bound GTP to GDP, which returns it to the inactive,
GDP-bound, state allowing its association with Gβγ dimer
to form Gαβγ-heterotrimeric complex [7–10]. In the case of
receptors possessing the tyrosine kinase activity the second
and the third steps are characterized by the functional
interaction between the regulatory and catalytic domains2 Journal of Amino Acids
located within multifunctional intracellular tail of these
sensor proteins, which leads to triggering the cascade of
phosphorylation-dephosphorylation of downstream regula-
tory and eﬀector proteins [11–13]. It should be mentioned
that the binding of ligand with the extracellular domain
of natriuretic peptide receptor NPR-C leads to interaction
between its short cytoplasmic region and G proteins; the
latter, the same as in the case of GPCR, become activated.
It seems quite likely that some tyrosine kinase receptors, the
epidermal growth factor (EGF) receptor in particular, have a
similar mechanism of action [11, 14, 15].
Nowadays it is commonly accepted that the regions of
signal proteins participating in their functional interaction
and, consequently, responsible for transfer of hormonal
signal to cell are rather short and usually contain 8 to 20
amino acid residues [16]. Using diﬀerent approaches of
molecular biology, it is shown that in a majority of cases
point mutations in these regions primarily responsible for
minimal changes in their conformation drastically inﬂuence
functionalactivityofsignalproteinsandblocksignaltransfer
via them. It is not unexpected therefore that the synthetic
peptides corresponding to these regions are able to trigger
signaling cascades in the absence of hormonal stimulus,
modulate protein-protein interaction, and inﬂuence the
functional activity of signal proteins induced due to changes
in their regulatory and catalytic sites. They have been used as
important tools in mimicking functional domains of signal
proteins, the component of hormonal signaling systems. The
present review is devoted to the achievements and perspec-
tives of the study of hormonal signaling systems described
in terms of the peptide strategy, a new perspective approach
of biochemistry and molecular endocrinology, based on
application of synthetic peptides as probes corresponding
to functionally important regions of signal proteins, such as
receptors of diﬀerent nature, heterotrimeric G proteins, and
the enzymes generating second messengers and responsible
for appropriate response of the cell to external signal.
2 .T h eR ec e pt o rso fth eSe rpe ntineT ype
As a rule, the serpentine type receptors interact with
heterotrimeric G proteins and share a highly conserved
transmembrane domain consisting of seven hydrophobic
TMs (TM1–TM7) and joined by three extracellular loops,
three intracellular loops (ICL1, ICL2, and ICL3), extracellu-
lar N-terminal domain, and cytoplasmic C-terminal domain
(CTD) [17]. The extracellular loops and N-terminal domain
form the external surface of TMC participating in ligand-
binding function of the receptor, while the ICLs and CTD
interact with a number of signal, regulatory and adaptor
proteins, including α and βγ subunits of G protein, RGS-
proteins, arrestins, PDZ domain-containing proteins, and G
protein-coupled receptor kinases [18, 19].
Therearenumerousdatagivingevidencethatinamajor-
ity of GPCRs the membrane-proximal amino- and carboxyl-
terminal regions of ICL3 (N- and C-ICL3), TM3/ICL2 inter-
face containing a highly conserved DRY-motif, and the N-
terminal region of CTD (N-CTD) forming in some GPCRs
an extra, fourth, loop are involved in the binding and
activation of G proteins and, thus, are responsible for signal
transduction via ligand-activated GPCR to intracellular
eﬀector proteins [1, 16, 20–24]( Figure 1). At present the
peptides corresponding to these intracellular regions of over
30 GPCRs have been synthesized and their regulatory, and
modulatory inﬂuence on cellular signaling studied [16, 21,
25–27]. They are successfully used as functional probes to
study GPCR-coupled signaling systems, allowing identiﬁca-
tion of molecular determinants in intracellular domains of
GPCRs responsible for their interaction with G proteins and
other signal proteins and elucidation of three-dimensional
structure and molecular dynamics of intracellular domains
of GPCR in inactive, agonist-free, as well as active, agonist-
bound, states, revealing the structural-functional organi-
zation of oligomeric protein-protein complexes, including
receptor molecules, and the role of these complexes in the
regulation and control of signal transduction.
One of the ﬁrst receptors whose structural organization
was studied using the peptide strategy is the light-activated
sensor protein rhodopsin belonging to the most ancient
family of the serpentine type receptors. Proceeding from
the data that synthetic peptides corresponding to ICL2,
ICL3, and CTD of rhodopsin signiﬁcantly inhibit interaction
between light-activated receptor and Gt protein, transducin,
the conclusion was made that the intracellular domains of
rhodopsin participate both in binding and in activation of
Gt protein, which conﬁrms the results of molecular-genetic
and crystallographic studies of other authors [28, 29]. It is
shown that eﬀective interaction of peptide with Gt protein
needsinvolvementofdiﬀerentregionsofthesedomainssince
combination of two or three peptides, derivatives of ICL2,
ICL3, and CTD, as compared to one, gives a 30–50 fold
decrease of IC50 values for inhibitory eﬀects of peptides on
GTPase activity of transducin stimulated by light-activated
rhodopsin and leads to complete impairment of coupling
between the receptor and Gt protein.
A majority of biologically active GPCR-peptides corre-
spond to ICL3 and ICL2, which is in good agreement with
the important role of these loops in productive interaction
of GPCR with G proteins and in hormone-induced signal
transfer from the receptor ligand-binding site to the enzymes
generating second messengers (Table 1). The peptides,
derivatives of ICL3 and ICL2 of Gs-coupled β-adrenergic
receptors (ARs) and Gi/o-coupled α2-AR, selectively bind
with G proteins, stimulate their functional activity, trigger
signaling cascade in the absence of hormonal stimulus,
inhibit the activation of their cognate receptors by selective
AR agonists, as it is shown for peptides derived from the
sequence 259–273 of β2-AR ICL3 and the sequence 361–
373 of α2-AR ICL3 [30–37]. In the case of the D1-a n d
D2-dopamine receptors (DRs), the 5-hydroxytryptamine
receptors (5-HTR) of the type 1 and type 6 as well as the
m2-a n dm 4-muscarinic acetylcholine receptors (MChRs),
all of which are coupled with Gs (D1-DR, 5-HT6R) or
Gi/o proteins (D2-DR, 5-HT1A,1B,1DR, m2/4-MChR), and also
m3-MChR coupled with Gq protein it is shown that the
peptides, derivatives of the membrane-proximal regions of
ICL3, especially C-ICL3, selectively bind and activate GJournal of Amino Acids 3
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Figure 1: The regions of GTP-bound Gαi1 subunit (yellow)r e s p o n -
sible for its speciﬁc interaction with ligand-activated receptor.
proteins and inhibit their functional interaction with their
cognate receptor upon agonist activation [30, 32, 38–44]
(Table 1).
There are many works demonstrating that the peptides
corresponding to ICL3 of GPCRs that are activated by the
peptide and protein hormones inﬂuence GPCR-signaling
with high eﬃciency and selectivity. The ICL3-peptide 237–
261 of the δ-opioid receptor blocks high-aﬃnity binding of
δ-agonists, signiﬁcantly decreases Gi/o-mediated AC inhibi-
tion and PLC activation following the stimulation of the δ-
opioid receptor, but has no inﬂuence on Gs-a n dG q-coupled
signaling cascades regulated via the same receptor [45]. The
peptides corresponding to ICL3 of the luteinizing hormone
receptor, the follicle-stimulating hormone (FSH) receptor,
the relaxin receptor of the type 1 (RXFP1), the glucagon-like
peptide-1 receptor (GLP1Rs) and the parathyroid hormone
receptor selectively activate distinct types of G proteins and
inﬂuencesignaltransductionviatheircognatereceptors[46–
53]( Table 1).
The cyclic and dimeric forms of GPCR-peptides, as a
rule, possess higher activity compared with linear peptides
as their three-dimensional structure is more similar to
that of the corresponding loop in intact receptor. Among
the peptides, derivatives of α2-AR ICL3, the most potent
activator of Gi/o proteins is dimeric constrain formed by
cross-linked peptides, derivatives of N- and C-ICL3 [31,
54]. A cyclic peptide 225–273 mimicking the full-length
ICL-3 of Gs-coupled V2-vasopressin receptor activates Gs
proteins and signiﬁcantly inhibits the AC activity stimulated
both by vasopressin and by guanine nucleotides, its action
on vasopressin-regulated AC system being more potent
compared with linear analogs [55].
The membrane-proximal N-CTD in some GPCRs forms
additional, fourth, intracellular loop and participates in the
interaction with GPCR-coupled downstream signal proteins,
G proteins in particular. The same refers to peptide 401–417
corresponding to N-CTD of the CB1-cannabinoid receptor,
which, like ICL3-peptides 301–317 and 329–344, stimulates
GTPγS binding of Gi proteins and inhibits forskolin-
stimulated AC activity [56–58]( Table 1). As for N-CTD-
peptide 645–653 of FSH receptor and its short analog, they
signiﬁcantly reduce FSH-stimulated estradiol synthesis in
cultured Sertoli cells and increase the GDP/GTP exchange
of G proteins in the rat testis membranes [46, 47]. The
fact that the peptides corresponding to the membrane-
proximal regions of ICL2, ICL3, and CTD of the type
1 angiotensin II receptor activate G proteins and inhibit
angiotensin II-induced stimulation of their GTPase activity
suggests these regions, the same as rhodopsin, to be involved
in the interaction with G proteins [59–62]. Concerning N-
formyl peptide receptor (FPR1), peptides 119–133, 122–144,
126–137, and 134–150 corresponding to ICL2, TM3/ICL2,
and ICL2/TM4 interfaces as well as CTD-peptides 308–
322, 319–340, and 322–336 directly interact with the C-
terminal region of Gαi/o, inhibit interaction of Gi/o proteins
with hormone-activated receptor, and decrease high aﬃnity
ligand binding to the receptor, while peptides 210–224, 227–
239, and 230–245 corresponding to ICL3, TM5/ICL3, and
ICL3/TM6 interfaces have little or no inﬂuence on G protein
and receptor activities and so do not interfere with their
coupling [63, 64]. It is not typical of G protein-binding and
-activating surfaces of the receptor to be formed by ICL2 and
CTD, so much so as ICL3 is not involved in interaction with
G proteins.
Despite the fact that ICL1 in a majority of GPCRs does
not participate in interaction with G proteins, peptide 39–51
corresponding to ICL1 of prostacyclin receptor speciﬁcally
interacts with the C-terminal region of Gαs and, thus,
activates Gs protein and stimulates AC activity. All this
indicates an important role of ICL1 of this receptor in
Gs protein coupling [65, 66]( Table 1). Another example is
ICL1 of GLP1R participating, like ICL3, in the interaction
with G proteins. The evidence for this stems from the fact
that peptide 169–176 corresponding to ICL1 of GLP1R
signiﬁcantly activates Gs and Gi proteins and inﬂuences
hormone-stimulated AC activity [53].
The action of many GPCR-peptides on G proteins is
very selective (Table 1). N-CTD-peptide 401–417 of CB1-
cannabinoid receptor decreases signiﬁcantly the interaction
of its cognate receptor with Gαi3 subunit, but not with Gαi1
and Gαi2, whereas peptides 301–317 and 329–344 disturb
receptor-mediated activation of Gαi1 and Gαi2 subunits, but
not Gαi3 [56, 57]. Peptide 483–497 corresponding to C-ICL3
of Gq-coupled m3-MChR at micromolar concentrations
selectively activates Gq but not Gi2 proteins [43], while
peptide 260–267 corresponding to C-ICL3 of Gs-coupled
D1-DR selectively activates Gs proteins [38]. Peptides 206–
224, 214–231, and 213–225 derived from N-ICL3 of D2-
DR, 5-HT1AR, and 5-HT1DR and peptides 382–400 and
285–298 derived from C-ICL3 of m4-MChR and 5-HT1DR
stimulate preferably Gi/o proteins and have little or no eﬀect
on the other G protein types [30, 32, 40–42]. The N-
ICL3-peptide 216–231 of the type 1 angiotensin II receptor
coupled with the Gi/o and with the Gq/11 proteins selectively
activates puriﬁed Gi/o proteins, while C-ICL3-peptide 230–
241 activates puriﬁed Gq/11 proteins [59, 61]. We have
shown that peptides 615–629 and 258–268 corresponding4 Journal of Amino Acids
Table 1: The peptides, derivatives of signal proteins, and their biological activity.
Signal protein Sequence Activity References
α2-AR (C-ICL3)
RWRGRQNREKRFTC361−373 and its dimeric
constrain with N-ICL3-peptide
RIYQIAKRRTR233−243
Both selectively stimulate Gi/o
proteins and inhibit α2-AR
agonist-stimulated GTPase activity
[30–32]
β2-AR (C-ICL3) RRSSKFCLKEKKALK259−273
Selectively stimulates Gs proteins
and decreases regulatory eﬀects of
β2-AR agonists
[33–35]
D1-DR (C-ICL3, I),
5-HT6R( C - I C L 3 ,I I )
FKMSFKRETKVLKTLSV260−276 (I);
KHSRKALKASL258−268K (II)
Stimulate Gs proteins and AC
activity, decrease the stimulating
eﬀects of D1-DR (peptide I) and
5-HT6R( I I )o nA Cs y s t e m
[38, 39]
D2-DR (N-ICL3, I),
5-HT1AR (N-ICL3,
II); 5-HT1BR
(C-ICL3, III);
5-HT1DR (N-ICL3,
IV; C-ICL3, V);
m4-MChR (C-ICL3,
VI)
VYIKIYIVLRRRRKRVNTK206−224 (I);
LYGRIFRAARFRIRKTVK214−231 (II);
ARERKATKTL307−316 (III);
LYGRIYVAARSRI213−225 (IV);
RKRISAARERKATK285−298 (V);
RNQVRKKRQMAARERKVTR382−400 (VI)
Selectively activate Gi/o proteins and
inhibit forskolin-stimulated AC
activity in the absence of hormone;
inhibit signaling via their cognate
Gi/o-coupled receptors
[30, 32,
39–42]
m3-MChR (C-ICL3) LVKEKKAAQTLSAILL483−497
Selectively activates Gq and
inﬂuences m3-MChR-mediated
signaling
[43]
δ-opioid receptor
(ICL3) MGRLRSVRLLSGSKEKDRSLRRITR237−261
Blocks δ-agonist-induced PLC
activation, Ca2+ release and cAMP
signaling
[45]
Luteinizing hormone
receptor; FSH
receptor (C-ICL3, II);
relaxin receptor
RXFP1 (C-ICL3, III);
parathyroid hormone
receptor (C-ICL3, IV)
FAVQNPELMATNKDTKIAKK551−570 (I),
HIYLTVRNPNIVSSSSDTRIAKR533−555 (II),
and EIRNQVKKE(Nle)ILAKR615−629 (III)
and their short analogs;
EYRKLLK402−408 (IV)
Activate preferably Gs proteins and
stimulate the basal AC activity,
inhibit agonist-induced signaling
via their cognate receptors
[46–52]
GLP1R (ICL1 and
ICL3)
FRHLHCTR169−176;
IVIAKLKANLMCKTDIKCRLAK330−351
Activate preferably Gs and Gi
proteins, inhibit hormone-
stimulated AC activity
[53]
V2-vasopressin
receptor (ICL3)
Cyclo-QVLIFREIHASLVPGPSERAG-
RRRRGRRTGSPSEGAHVSAAMAKT-
VRMT225−273
Decreases the aﬃnity of agonist for
the receptor and inhibits
vasopressin-stimulated AC activity
[55]
CB1-cannabinoid
receptor (N-ICL3, I;
C-ICL3, II, and
N-CTD, III)
KAHSHAVRMIQRGTQKS301−317 (I);
QVTRPDQARMDIRLAK329−344 (II);
RSKDLRHAFRSMFPSCE401−417 (III)
Selectively stimulate diﬀerent
isoforms of the α-subunits of Gi
proteins and signiﬁcantly inhibit
AC activity
[56–58]
Angiotensin II
receptor of the type 1
(ICL2, I; N-ICL3, II;
C-ICL3, III, N-CTD,
IV)
DRYLAIVHPMKSR125−137 (I);
TLIWKALKKAYEIQKN216−231 (II);
KNKPRNDDIFRI230−241 (III);
FLGKKFKKYFLQL304−316 (IV)
Inhibit angiotensin-induced
activation of G proteins and the
eﬀector enzymes; peptide II
selectively activates Gi/o proteins,
peptide III Gq/11 proteins
[59–62]
FPR1 (ICL2, I;
N-CTD, II)
CVLHPVWTQNHR126−137 (I);
FRERLIHALPASLER308−322 (II)
Activate in a PTX-dependent
manner Gi proteins; peptide II
inhibits high aﬃnity agonist
binding to the receptor and its
coupling to Gi protein
[63, 64]
Prostacyclin receptor
(ICL1) SARRPARPSAFAV39−51 Selectively stimulates Gs proteins
and the basal activity of AC [65, 66]
Insulin receptor
(tyrosine kinase
region)
N-stearyl-TRDIYETDYYRK1142−1153
Increases insulin- and
vanadate-stimulated
phosphorylation of IR; signiﬁcantly
enhances insulin-induced
stimulation of PI3K and MAPK
activities
[67]Journal of Amino Acids 5
Table 1: Continued.
Signal protein Sequence Activity References
Insulin receptor
(C-terminal region) N-stearyl-SSHCQREEAGGRDGG1293−1307
Enhances insulin-stimulated
autophosphorylation; increases
insulin-stimulated PI3K and MAPK
activities
[68]
EGF receptor
(N-terminal region of
the juxtamembrane
domain)
RRREIVRKRTLRR646−658 Activates Gs proteins, inﬂuences
activity of Gi proteins [69]
NPR-C (cytoplasmic
domain)
KKYRITIERRNH461−472;
RRNHQEESNIGK469−480;
RRNHQEESNIGKHRELR469−485;
HRELREDSIRSH481−492 and their analogs
Inhibit the basal, forskolin- and
hormone-stimulated AC activity;
selectively increase GTP binding
activity of Gi1 and Gi2 proteins;
stimulate PLCβ3 activity; inhibit
hormone-stimulated DNA synthesis
in vascular smooth muscle cells;
induce smooth muscle contraction
[70–72]
NPR-C (extreme
C-terminal region of
the cytoplasmic
domain)
GKHRELREDSIRSHFSVA479−496
Inhibits ANP(4–23)-induced Gi
protein activation and cellular
responses acting as a competitive
inhibitor of ANP(4–23)-mediated
signaling
[71]
Gαt IKENLKDCGLF340−350
Stabilizes the active state of opsin
and meta-II-rhodopsin and
meta-Ib-rhodopsin;
[73–76]
Gαs
RVFNDARDIIQRMHLRQYELL374−394 and
its short analogs
Inhibit transduction of hormonal
signal via Gs-coupled receptors [77]
Gαs ( S w i t c hIa n dI I
regions, resp.)
RCRVLTSGIFETKFQVDK199−216;
FDVGGQRDERRKWIQ-
CFNDVTAIIFV222−247
Increase the basal and
forskolin-stimulated AC2 and AC6
activities; inhibit Gαs-stimulated
activity of both AC isoforms;
behave as partial agonist
[78]
Gαs (α3-β5 region) EALNLFKSIWNNRWL-RTIS268−286
Inhibits the basal and
forskolin-stimulated activities of
AC2 and AC6; signiﬁcantly
decreases the Gαs-stimulated
enzyme activity
[78]
AC1 (C1b subdomain)
IKPAKRMKFKTVCYLLVQLMHCRKMF-
KA495−522
(pAC28, C1b)
Binds CaM with high aﬃnity in a
Ca2+-independent manner; inhibits
CaM-stimulated AC activity with
IC50 equal to 500 nM
[79, 80]
AC1 (C2a subdomain) TEEVHRLLRRGS-YRFVCRGKV1024−1044
(pVLG, C2a)
Binds CaM with low aﬃnity in a
Ca2+-dependent manner; inhibits
CaM-stimulated AC activity with
IC50 is 10μM
[80]
AC2 (C2 domain)
YTESDVNKEGLECLRLLNEIIADFD-
DLL899−926 (α2, I);
SKPKFSGVEKIKTIGSTYMAAT927−948
(β2-β3, II);
DAINKHSFNDFKLRVGINHGPVIA-
GVIGAQK984−1015
(α3-β4, III)
All peptides inhibit αs-a n d
forskolin-stimulated activities of
AC2 and AC6; peptides I and III
inhibit the basal AC activity;
peptide I decreases
Mn2+-stimulated activity
[81]
AC6 (C1 domain)
AAENHCLRIKILGDCYYC427−444
(α2-β2-β3, I);
IHSGRVHCGVLGLRKWQFDVWSN-
DV487−511
(β4-β5-α4, II)
Both peptides inhibit αs-a n d
forskolin-stimulated AC activities;
peptide II inhibits the basal activity
of both AC2 and AC6
[81]6 Journal of Amino Acids
Table 1: Continued.
Signal protein Sequence Activity References
PLCβ1b
N-Myristoyl-TPPNPQALKW1164−1173 (I);
GEGSSSVLSESCHEDPSVPPNFTPP-
NPQALKW1142−1173 (II)
Both peptides dissociate the enzyme
from membrane and inhibit PLC
stimulation by hormones; peptide
II prevents cardiomyocytes
hypertrophy
[82, 83]
PLCβ3 QEENTQL1161−1167
Signiﬁcantly inhibits intracellular
calcium response to selective
agonists of mGluR
[84]
PLCγ GLYRKAMRLRYPV724−736, and its
N-myristoylated analogs
Speciﬁcally inhibit PLC activity and
PLC-dependent cellular processes [85]
PLCδ1 (IQ-peptide) VRSQVQHKPKEDKLKLVPELS473−493 Inhibits PLC activity; binds CaM in
Ca2+-independent manner [86]
PLCδ1 N-Myristoyl-
TIPWNSLKQGYRHVHLL747−763 Inhibits FSH-induced Ca2+ inﬂux [87]
Regulatory
p85-subunit of PI3K
(C-terminal region of
N-terminal SH2
domain)
WNVGSSNRNKAENLLRGKR11−29
Exhibits binding speciﬁcity and
aﬃnity for PI 3,4,5-P3 and inhibits
PI 3,4,5-P3-binding to the p85
subunit
[88]
PKCζ
(pseudosubstrate
region)
N-Myristoyl-SIYRRGARRWRKL114−126
Inhibits PKCζ activity; stimulates
Akt, ERK1/2, p38 MAPK and eNOS
activity
[89]
PKCη
(pseudosubstrate
region)
N-Myristoyl-
RKRQRAMRRRVHQING156−171
Inhibits PKCη activity; stimulates
eNOS phosphorylation [89]
to C-ICL3 of the relaxin receptor RXFP1 and 5-HT6R
at micromolar concentrations stimulate AC activity and
increase the basal level of GTP binding of Gs proteins but do
not aﬀect the other types of G proteins, in particular the Gi
proteins associated with AC in the inhibitory manner [39].
The treatment of membrane fraction with pertussis toxin
(PT) inactivating Gi proteins does not inﬂuence the eﬀects
of peptides 615–629 and 258–268, whereas the treatment
with cholera toxin impairing the function of Gs proteins
blocks these eﬀects. In the presence of peptide derived
from C-terminal segment of the Gαs subunit the eﬀects
of both peptides are signiﬁcantly decreased. This is due to
competition between the full-size Gαs and C-terminal Gαs-
peptide for binding with GPCR-peptide, and is the evidence
of participation of Gs protein in the mechanism of action of
GPCR-peptide. Besides, the peptide corresponding to Gαi C-
terminalsegmentdoesnotaﬀecttheactivityofpeptides615–
629 and 258–268, derivatives of Gs-coupled receptors. The
C-ICL3-derived peptide 300–316 of Gi-coupled 5-HT1BR
increases GTP binding activity of Gi protein but does not
aﬀect the other G proteins. This eﬀect is blocked by PT
treatment and reduced in the presence of C-terminal Gαi-
peptide [39].
The G protein-interacting regions of GPCRs are usually
positively charged and contain BBXXB, BBXB, and the
related motifs, where B is a basic amino acid residue (Arg
or Lys) and X is another residue [30, 90, 91], speciﬁcally
interact with the negatively charged C-terminal region of
Gα subunits that is of prime importance for recognition
and eﬀective interaction of diﬀerent types of G proteins
with ligand-activated GPCR [42, 92–94]. In addition to the
extreme C-terminus of Gα, the α4 helix and the α4/β6
loop rich in negatively charged amino acid residues also
participate in a receptor-G protein coupling [32]. As a result,
the presence of BBXXB and the related motifs in GPCR-
peptides, derivatives of receptor intracellular domains, is a
very important structural feature required for their eﬀective
and selective interaction with G proteins. The substitution
of the positively charged Lys221 and Arg222 in C-terminal
segment of N-ICL3-peptide 208–226 of Gi/o-coupled D2-DR
by alanine residues leads to a 3-fold reduction in its aﬃnity
for Gαi/o [42]. Consistent with that, mutant D2-DR with the
substitution of segment RRRR217−220 in N-ICL3 by AAAA is
not capable of eﬀective interaction with Gi/o proteins and
is insensitive to agonist activation. These ﬁndings support
the view that charge-charge complementation has a very
important role in receptor-Gα coupling [95, 96].
Thepeptidestrategymakesitpossibletoproduceanalogs
of GPCR-peptides with a higher biological activity and to
deliver them to the intracellular eﬀector proteins of the
target cells, which is very important for their application
as a new generation of highly eﬀective and selective GPCR-
based drugs. The most perspective way to achieve this goal
is modiﬁcation of GPCR-peptides using either hydrophobic
radicals, for example, C12–C18 acyl or steroid group, or
hydrophobic TM fragment; they mimic the receptor TM,
maintain the peptide conformation close to that in native
receptor, and, ﬁnally, allow the transfer of peptide across theJournal of Amino Acids 7
plasma membrane. Such cell-penetrating lipidated peptides
are designated as pepducins. The latter corresponding to
ICLs of the protease-activated receptors (PAR1, PAR2,
PAR4), the chemokine receptors (CXCR1, CXCR2, CXCR4,
CCR5), the sphingosine-1-phosphate (S1P) receptor, the
relaxin receptor RXFP1, α1B-AR, 5-HT1BR, and 5-HT6R
function as intracellular agonists or antagonists of their
cognate receptors and their action is realized at the stage of
speciﬁc interaction between the receptor and G protein on
the intracellular plasma membrane surface [39, 49, 50, 97–
102]. Pepducins can be used to control platelet-dependent
hemostasis and thrombosis, tumor growth, invasion, angio-
genesis, as well as to prevent some inﬂammatory diseases
[26, 27, 100, 103–109].
With respect to the speciﬁcity and eﬃciency of action
on their cognate receptors, pepducins signiﬁcantly surpass
unmodiﬁed analogs, which makes them very perspective
selective regulators of hormonal signaling systems [39, 50,
98–100, 105, 110, 111]. Peptide Pal-RCLSSSAVANRS295−306
(P1pal-12) corresponding to N-ICL3 of Gq/11-a n dG i-
coupled PAR1 functions as a selective PAR1 antagonist and
inhibits the increase in inositol triphosphate production
and concentration of intracellular Ca2+ induced by agonist-
activatedreceptor,signiﬁcantlydecreasesplateletaggregation
in response to PAR1 agonist SFLLRN and the vasorelaxation
caused by other PAR1 agonist TFLLR-amide in the rat
aorta, but does not aﬀect the vasorelaxation caused by
PAR2 agonist SLIGRL-amide, neither does it inhibit PAR4-
dependent platelet aggregation [98, 112]. This peptide has
no eﬀect on the aggregation in response to agonists of the
thromboxane, ADP, collagen, and GPIb/IX/V receptors the
same as the lack of eﬀect on the response to interleukin-
8, stromal-derived factor 1α,S 1 P ,m o n o c y t ec h e m o t a c t i c
protein-1, RANTES (Regulated on Activation Normal T
cell ExpreSsed) in endothelial cells, or the migration of
recombinantly transfected HEK293 cells to ligands of PAR2,
PAR4, CXCR1, CXCR2, CCR5, or S1P receptors [98, 105].
Peptide Pal-RCLSSSAVANRSKKSRALF295−313 (P1pal-19), a
derivative of PAR1 ICL3, possesses the activity of PAR1 ago-
nist and, like selective PAR1 agonists TFLLR and SFLLRN,
stimulates the Gq and Gi/o proteins and PLCβ activities,
produces endothelial NO-dependent relaxation in the rat
aorta, and promotes prostaglandin E2 release in the human
lungepithelialcellsandtheratgastricmucosalepithelialcells
[97, 98, 112]. The action of P1pal-19 is very speciﬁc to PAR1
and its inﬂuence is drastically reduced or completely blocked
in cultured cells and the tissues where its cognate receptor is
absent or mutant form of PAR1 is expressed.
The ICL3-peptide Pal-SGRRYGHALR274−283 (P4pal-10)
of PAR4 functions as an antagonist of its cognate receptor
and a partial antagonist of PAR1. It completely inhibits PLCβ
stimulation and Ca2+ response induced by PAR4 agonist
AYPGKF-amide and decreases the analogous eﬀects of PAR1
agonist SFLLRN-amide by 36%. P4pal-10 completely blocks
platelet aggregation induced by PAR4 agonist and partially
inhibits PAR1 agonist-induced aggregation, whereas it has
no eﬀect on the aggregation of platelets induced by a series
of agonists of the GPCRs which do not belong to the
PAR family, neither on the migration of human neutrophils
to interferon-γ-inducible protein-10, stromal-derived factor
1α, and S1P but completely blocks migration to thrombin
activating both PAR1 and PAR4 [98, 111]. ICL1-peptide Pal-
ATGAPRLPST103−112 (P4pal-i1) of PAR4 is more selective
compared with peptide P4pal-10. It completely blocks the
chemotactic response realized via PAR4 and prevents platelet
aggregation triggered by PAR4 agonist AYPGKF-amide but
does not inhibit the chemotactic response of PAR1 and
does not aﬀect platelet aggregation induced by PAR1 agonist
SFLLRN-amide [106, 113]. When P4pal-i1 is combined with
thrombin inhibitor bivalirudin, inhibition of human platelet
aggregation and suppression of arterial thrombosis in guinea
pigs increases to a much higher degree than with bivalirudin
alone [106]. The data concerning thrombolytic action of
peptides P4pal-10 and P4pal-i1 and ICL-peptides of other
PARs show that on their basis it is possible to have receptor-
selective drugs for antiplatelet therapy [114].
Pepducins have been used to study the role of the
chemokine receptors in sepsis and systemic inﬂammation
and are found to improve survival and prevent systemic
inﬂammation and overactivation of the coagulation system
in sepsis. Pepducins corresponding to ICL1 and ICL3 of
the chemokine receptors CXCR1 and CXCR2 function as
selective antagonists of these receptors and inhibit Gs-
mediatedeﬀectsofinterleukin-8,aligandforthesereceptors,
neutrophil chemotaxis toward interleukin-8 in particular,
as well as reverse disseminated intravascular coagulation
and liver failure in septic mice and prevent the lethal
sequel of sepsis. At the same time, pepducins corresponding
to ICL1 and ICL2 of the chemokine receptor CXCR4
selectively interact with their cognate receptors and cause
a massive leukocytosis consistent with the role of CXCR4
in stromal-derived factor 1α neutrophil homeostasis, while
the pepducins do not aﬀect interleukin-8-mediated signaling
pathways and have no eﬀect on survival [100, 105].
We showed that peptide QVKKE(Nle)-
ILAKR619−629K(Pal) corresponding to C-ICL3 of the
Gs-coupled relaxin receptor RXFP1 stimulates AC activity
and Gs protein GTP binding and inhibits regulatory eﬀects
of relaxin on the AC system in the myocardium and brain,
which raises no doubt due to a high level of expression of
its cognate receptor, but is ineﬀective in the skeletal muscles
where there are no receptors [49, 50]. Palmitoylated peptide
KHSRKALKASL258−268K(Pal)A corresponding to C-ICL3
of 5-HT6Ri se ﬀective in the brain rich in 5-HT6R, but not
in respect to the AC system in the myocardium and testes
where these receptors are absent or expressed very little [39].
Alongside with high selectivity, pepducins are more
eﬃcient compared with their unmodiﬁed analogs. Actually,
RXFP1-peptide 619–629-K(Pal) stimulates relaxin-sensitive
AC system with greater eﬃciency compared with 15-mer
peptide 615–629 lacking fatty acid radical, while unmodiﬁed
11-mer peptide is not active in this case [50]. Palmitoylated
5-HT6R-peptide 258–268 has a stronger inﬂuence on Gs
proteins and AC than its unmodiﬁed analog [39]. PAR1-
peptide 295–313 lacking hydrophobic radical does not
stimulate Ca2+ ﬂuxes while its palmitoylated analog causes
a rapid Ca2+ transient [97].8 Journal of Amino Acids
These data give grounds to make a conclusion that
modiﬁcation by hydrophobic radicals is one of the most
perspective approaches to enhance both the selectivity and
eﬃciency of GPCR-peptides as regulators of hormonal
signaling systems. The main reason for high biological
activity of pepducins is the ability of their hydrophobic
radical to partition into the plasma membrane and to ﬂip
across lipid bilayer, thus shuttling the attached peptide to
the intracellular surface of the membrane and mediating
the eﬀective interaction of peptide portion of pepducin with
the complementary regions of the GPCR or G proteins
[115].
3.TheReceptorswithTyrosineKinaseActivity
In the 1990s the peptide strategy found wide application
with a view to identify signal-protein-interacting regions
in two best known receptors possessing tyrosine kinase
activity, the insulin receptor (IR) and the EGF receptor. The
IR belongs to the family of transmembrane glycoprotein
receptors activated by insulin, insulin-like growth factor-1
and other insulin-related peptides, and is composed of two
135-kDa extracellular α subunits which bind the hormone
and two 95-kDa transmembrane β subunits with intrinsic
tyrosine kinase activity. The main substrates of insulin-
stimulated phosphorylated IR are IRS and Shc proteins, but
thedataareavailablesuggestingthatIRisalsoabletointeract
with heterotrimeric G proteins and, thus, regulate G protein-
dependent signaling cascades [11, 15, 116].
The ﬁrst data concerning the regions capable of specif-
ically interacting with G proteins appeared in the early
1990s and were obtained with three synthetic peptides,
1039–1061, 1135–1156, and 1319–1333, corresponding to
thetyrosinekinasedomain(theﬁrsttwo)andtheC-terminal
domain (the third) located in the cytoplasmic tail of IR β
subunit [117]. They contain positively charged BBXXB and
the related motifs typical of G protein-activating sequence
of GPCRs. Peptide 1039–1061 induces a dose-dependent
stimulation of GTP-binding and GTPase activities of Gs
proteins, while peptide 1325–1345 containing a site for
tyrosine phosphorylation located in the C-terminal domain
of IR activates the Gi/o proteins [117], and peptide 1135–
1156 containing tyrosine residues critical for IR tyrosine
kinase activity stimulates GTP-binding of unusual 67kDa
G protein involved in the insulin signal transduction [118].
The Gi-activating eﬀect of C-terminal peptide 1325–1345 is
supported by the data obtained later on direct interaction
between insulin-activated IR with Gi2 protein and the
blocking of this interaction by PT [116, 119].
To identify IR regions participating in phosphorylation-
dephosphorylation cascade, a series of peptides containing
the most important tyrosine residues, the targets of tyro-
sine phosphorylation, and their derivatives with modiﬁed
tyrosines were synthesized and studied (Table 1). A tris-
sulfotyrosyl peptide 1142–1153 corresponding to the major
site of autophosphorylation inhibits dephosphorylation of
the IR in CHO cells overexpressing the human IR [67,
120]. An N-stearyl derivative of this peptide causes a
several-fold increase in insulin- and vanadate-stimulated
phosphorylation of IR and leads to a signiﬁcant enhance-
ment of insulin-induced stimulation of phosphatidylinosi-
tol 3-kinase (PI3-K) and mitogen-activated protein kinase
(MAPK) activities but has no eﬀect on the basal phos-
phorylation of IR. Maximal stimulation is observed with
50μM of N-stearyl peptide 1142–1153. Peptide 1293–
1307 corresponding to C-terminal domain of IR enhances
insulin-stimulated receptor autophosphorylation but has
no detectable eﬀects on the basal phosphorylation of IR
and on receptor dephosphorylation [68]. A stearyl ana-
log of peptide 1293–1307 also enhances insulin-stimulated
autophosphorylation and, additionally, induces a 2-3-fold
increase in both the activity of insulin-stimulated PI3-K, and
the level of tyrosine phosphorylation of MAPK in response
to insulin. The most pronounced inﬂuence of N-stearyl
derivativesofpeptides1142–1153and1293–1307oninsulin-
induced IR autophosphorylation and function, compared
with unmodiﬁed analogs, suggests that the intrinsic activity
of IR undergoes modulation, depending on the presence of a
fatty acid-acylated receptor fragment in cells. The expression
of a minigene encoding 23-mer peptide 1292–1315, the
longest analog of peptide 1293–1307, has no eﬀect on the
basal receptor tyrosine phosphorylation level but leads to
an increase in insulin-activated IR autophosphorylation that
in minigene-transfected CHO cells is about twice as high as
in control cells [121]. The stimulating eﬀects of insulin on
PI3-K and MAPK activities and thymidime incorporation
into DNA are also signiﬁcantly elevated in cells expressing
the minigene. These data indicate that peptides 1142–1153
and 1293–1307 and minigene-expressed peptide 1292–1315
bind to the regions in IR β subunit responsible for the
intrinsicactivityofthereceptorandfunctionalcouplingwith
downstreamsignalingproteins,suchasIRSandShcproteins,
PI3-K and MAPK. The action of the peptides and their
lipophilic derivatives is highly speciﬁc since the latter are
not capable of inhibiting dephosphorylation of EGF receptor
and do not inﬂuence ligand-induced phosphorylation of
both EGF receptor and insulin-like growth factor-1 receptor
which functionally and structurally resembles IR [67, 68,
121].
To identify the regions participating in IR tyrosine
kinase function, Van Obbergen and colleagues used another
approach based on antipeptide antibodies directed against
synthetic peptides corresponding to the regions localized
in the C-terminal domain of IR, such as 1270–1280,
1294–1317, and 1309–1326 [122–124]. Antipeptide IgG
recognizing acid-rich sequence 1270–1280 inhibits both
receptor autophosphorylation, at least on Tyr1146,T y r 1150,
and Tyr1151, the main targets of IR tyrosine kinase, and the
receptor-induced phosphorylation of poly(Glu80Tyr20)a n d
a peptide corresponding to the region 1142–1158 [123].
The antipeptide antibody directed to the region 1294–1317
inhibits phosphorylation of poly(Glu80Tyr20) and synthetic
peptides corresponding to the IR autophosphorylation sites
but does not inhibit receptor autophosphorylation. In addi-
tion, it decreases receptor-mediated phosphorylation of Src
homology/collagen and of IRS-1 protein by 52 and 30%,
respectively [124]. These data give strong evidence that
the C-terminal domain of IR interacts with signal proteinsJournal of Amino Acids 9
participating in the regulation and modulation of tyrosine
kinase activity of the receptor.
The EGF receptor one time penetrates the membrane
and contains a large extracellular domain that consists of
two ligand-binding and two cysteine-rich subdomains and
the intracellular tyrosine kinase domain. The binding of EGF
receptor to EGF causes receptor dimerization and induces
phosphorylation of tyrosine residues in tyrosine kinase
domain located in the intracellular tail of receptor, which
recruits many signaling proteins, such as PI3-K, PLC-γ,
PLD, Shc, and Grb2 proteins, phosphotyrosine phosphatase
1, and others, and transduces hormonal signal to diﬀerent
intracellular eﬀector proteins and systems [125]. In 1995 Sun
and colleagues revealed that EGF receptor-derived peptide
is able to stimulate G proteins [69]( Table 1). This ﬁnding
coincides very well with the data obtained in the recent years
about the direct interaction of diﬀerent types of G proteins
with EGF receptor and their role in EGF-mediated signaling
[11, 126, 127]. The synthetic peptide 646–658 corresponding
to the membrane-proximal segment of the juxtamembrane
domain located in the cytoplasmic tail of EGF receptor
stimulates GTP-binding and GTPase activities of Gs protein
coupled to this receptor. In addition, it increases the Gi
protein GTPase activity without aﬀecting the GTP-binding
activity, which suggests that the juxtamembrane domain is
able to stimulate Gs proteins and inactivate Gi proteins.
Peptide with phosphorylated residue Thr654, the main target
for protein kinase C (PKC), does not aﬀect Gs protein and
retains the ability to stimulate the GTPase activity of Gi
protein. The incorporation of negatively charged phosphate
group decreases the net positive charge of peptide and,
in addition, destabilizes its helical conformation, which is
functionally important for eﬀective interaction of peptide
with the Gαs subunit, and, hence, blocks the activation of
Gs protein by the phosphorylated peptide. It is supposed
that in the case of Gi protein the phosphorylated peptide
induces the dissociation of the heterotrimeric complex to
givemonomericGαi subunitand,thus,stimulatesitsGTPase
activity. These data speak in favor of the fact that phospho-
rylation of tyrosine residues in EGF receptor, as well as of
serine and threonine residues in GPCRs, aﬀects selectively
their coupling with diﬀerent types of G proteins, Gs and Gi
proteins in particular. It was shown, in addition, that peptide
646–658 with the reverse sequence (RRLTRKRVIERRR) also
activates Gs protein, which indicates that orientation of
peptide 646–658 is of no importance for its interaction with
G protein and the main role in this process is given to
the secondary structure of peptide (α helix is optimal) and
spatial distribution of positively charged amino acids [69].
As has been shown recently using the other biochemical
approaches, Gαi1 and Gαi3 form the complex with ligand-
activated EGF receptor and are required for phosphorylation
of Grb2-associated binding protein 1 and its subsequent
interaction with p85 subunit of PI3-K in response to EGF,
whereas the coupling between EGF receptor and Gs protein
leads to activation of cAMP-dependent signaling pathways
[11, 127]. Thus, the peptide strategy came to be a starting
point for further investigations in which the role of G
proteins in the tyrosine kinase receptor-mediated signaling
has been established.
A new era of application of the peptide strategy in the
study of structural-functional organization of the tyrosine
kinase receptors is connected with quantitative proteomics
using pull-down experiments with pairs of phosphorylated
and nonphosphorylated synthetic peptides, corresponding
to phosphotyrosine-containing sites in the intracellular
domains of these receptors [13, 128, 129]. The receptors
possessing tyrosine kinase activity have, as a rule, several
docking sites for each of the interacting proteins-partners.
The EGF receptor and the related to it ErbB4 receptor have,
for example, four to seven docking sites for Grb2 protein
three to four sites for Shc protein, while ErbB3 receptor
lacking the functional kinase domain has a large number of
binding sites for PI3-K. Using a series of synthetic peptides
corresponding to tyrosine phosphorylation sites of EGF and
ErbB4 receptors, the new recognition motifs for Shc protein
were detected. It was shown that the STAT5 protein, a latent
cytoplasmic transcription factor, is a new partner of both
receptors; it speciﬁcally interacts with Tyr978-a n dT y r 998-
containing sites of EGF receptor and with Tyr984-containing
site of ErbB4 receptor. It should be pointed out that both
phosphorylated and nonphosphorylated forms of peptides
are used to study the role of tyrosine phosphorylation
for eﬀective and selective interaction of these receptors
with their partners [129]. The assay based on the interac-
tion between receptor-derived phosphotyrosine-containing
peptides and proteins-partners is extremely speciﬁc and
capable of conforming the binding motifs identiﬁed so far
and detecting new target sequences, which is conﬁrmed
by the fact that all identiﬁed binding partners contain
either SH2- or PTB-domains speciﬁcally interacting with
phosphotyrosine-containing motifs, and phosphotyrosines
not expected to have binding partners do not show any
proteins with signiﬁcant ratios. This assay is very sensitive,
since the peptide-protein interaction screen is validated for
binding constants as low as at least 5μM, but it is likely to
work with much lower aﬃnity interactions [128, 129].
4.NatriureticPeptideClearanceReceptor
The natriuretic peptide receptor of C-type (NPR-C) belongs
to natriuretic peptide receptors but lacks gyanylyl cyclase
catalytic domain. It is a disulﬁde-linked homodimer having
a single TM, a large extracellular domain of 440 amino acids,
and a short 37-amino acid cytoplasmic tail. The binding
of the NPR-C with atrial natriuretic peptide (ANP) and its
several fragments induces the activation of Gi proteins and
inhibition of AC activity and NPR-C-mediated decrease in
cAMP levels contributes to the activation of PLC signaling
[130].
A 37-mer peptide corresponding to the cytoplasmic
tail of NPR-C and a similar peptide with 10 additional
N-terminal amino acids derived from receptor TM in a
GTP-dependent manner inhibit AC activity in the cardiac
membranes with Ki of about 1nM [131]. Preincubation
of the membranes with PT blocks AC inhibitory eﬀect of
peptides, which suggests that the latter, like ANP, inhibit the10 Journal of Amino Acids
enzyme activity via PT-sensitive Gi/o proteins. To identify in
the cytoplasmic domain of NPR-C the segments responsible
for inhibition of AC activity the series of 8–18-mer peptides
corresponding to diﬀerent regions of this domain were
synthesized and examined as regulators of the Gi/o proteins
and AC activities [70, 132]. These peptides contain typical
Gi/o-activating sequences and have two basic amino acids
at the N terminus and BBXB or BBXXB motifs at the C
terminus [30, 133].
Pagano and Anand-Srivastava showed that positively
charged peptides 461–472, 469–480, 469–485, and 481–492
in a concentration-dependent manner inhibit the basal AC
activity with Ki between 0.1 and 10nM and signiﬁcantly
decrease forskolin-, glucagon- and isoproterenol-stmulated
AC activity in A-10 vascular smooth muscle cells and their
inhibitory eﬀe c t sa r ec o m p l e t e l ya t t e n u a t e db yP Tt r e a t m e n t
[70]( Table 1). These peptides inhibit the stimulation of
DNA synthesis induced by angiotensin II, endothelin, and
arginine vasopressin but do not inﬂuence the basal level
of DNA synthesis in these cells [72]. It was also shown
that peptide 461–472 inhibits both the phosphorylation of
ERK1/2 and AKT protein kinases and the increase of Gαi
subunit expression induced by vasoactive peptide hormones.
In addition, in the presence of this peptide the inhibitory
eﬀects of PD-98059, a MEK inhibitor, and of wortmannin,
a PI3-K inhibitor, on hormone-induced DNA synthesis
are potentiated. These data suggest that positively charged
peptides containing Gi/o-activating sequences, irrespective of
their location within NPR-C cytoplasmic domain, inhibit
proliferative responses of the muscle cells to vasoactive
peptide hormones realized via Gi/o protein and MAPK/PI3-
K/AKT signaling pathways [72].
Murthy and Makhlouf [132] synthesized and studied
the related peptides 467–482, 469–485, and 479–496 cor-
responding to the N-terminal, middle, and C-terminal
regions of the intracellular domain of NPR-C. Peptide 469–
485, the same as the selective NPR-C agonist ANP(4–
23), signiﬁcantly increases the GTP binding to Gαi1 and
Gαi2 subunits but not to Gαi3,G αs,a n dG αq/11 subunits,
stimulates phosphoinositide hydrolysis by activating PLCβ3
via the Gβγ subunits of both Gi1 and Gi2 proteins with
an EC50 of 1.3μM, and inhibits forskolin-stimulated AC
activity by 64% in solubilized tenia coli smooth muscle
membranes. In the presence of this peptide the stimulatory
eﬀects of ANP(4–23) on Gi1 and Gi2 proteins binding
and the PLCβ3 activity are increased by 187, 289, and
43%, respectively. Peptide 467–482 with a partial C-terminal
BBXXB-motif is a less eﬀective activator of the Gi1 and Gi2
proteins and PLCβ3. Peptide 479–496 does not inﬂuence
the basal level of G protein binding and PLC activity but
decreases the stimulatory eﬀects of both ANP(4–23) and
peptide 469–485 on Gi1 and Gi2 proteins binding and PLCβ3
activity. Peptide 469–485 induces contraction in saponin-
permeabilized smooth muscle cells and enhances the ability
of ANP(4–23) to induce contraction. Peptide 479–496 has
no eﬀect on contraction but inhibits ANP(4–23)-induced
contraction. It follows that peptide 479–496 inhibits Gi
protein activation and cell responses mediated by ANP(4–
23) and peptide 469–485, suggesting that the positively
charged motif KHRELR491−496 localized at the C-terminus
of this peptide mediates binding but not activation of G
protein,thus,causingpeptide479–496toactasacompetitive
inhibitor of Gi p r o t e i na c t i v a t i o n[ 132]. Summing up, using
the synthetic peptides the selective Gi protein-binding and
-activating determinants within cytoplasmic tail of NPR-
C participating in activation of PLC-dependent signaling
cascades responsible for muscle contraction were identiﬁed,
which coincides very well with the later mutational and
deletion studies [71].
5. HeterotrimericG Proteins
Heterotrimeric G proteins consisting of α, β,a n dγ subunits
are divided according to the nature of α subunit into
four main families, Gs/olf,G i/o,G q/11,a n dG 12/13,b a s e d
on structural and functional similarity [134]. In mammals
there are 21 Gα subunits encoded by 16 genes, six Gβ
subunits encoded by ﬁve genes, and 12 Gγ subunits. Gβ and
Gγ subunits form a functionally active Gβγ-heterodimeric
complex;itanchorsinthemembraneanddoesnotdissociate
under nondenaturing conditions. Gs proteins activate AC
and calcium channels, Gi proteins inhibit AC and activate
potassium channels, Go proteins stimulate PLC, activate
potassium channels, and inactivate calcium channels, Gq/11
proteinsactivatePLC,andG12/13 proteinsstimulateRho/Rho
kinase activity [4, 5, 10].
Several diﬀerent regions of Gα subunit are implicated
in recognition of GPCRs and are responsible for the
speciﬁcity of receptor-G protein interaction, but the extreme
C-terminal region is of special importance for eﬀective
and selective interaction of diﬀerent types of G proteins
with ligand-activated GPCR [7, 42, 92, 94]. This nega-
tively charged region of Gα binds with positively charged
intracellular regions of GPCRs. It seems quite likely that
GPCRs use C-terminal region as a “latch” to alter the
conformation of the α5h e l i xo fG α subunit (Figure 2). The
conformational changes of the α5 helix give rise to a change
intheconformationoftheβ6/α5loop,destabilizeitscontacts
with the guanine ring of GDP, and lead to the GDP/GTP
exchange [135]. In addition to the extreme C-terminus of
Gα, the α4 helix, and the α4/β6 loop, both localized close
to the C-terminus, also directly participate in a receptor-G
protein coupling and in the case of Gαi subunit determine
its speciﬁcity [32]. It was shown that an anionic cluster of
Gαi subunit α4 helix, especially negatively charged Glu308
and uncharged Gln304, directly interact with the positively
c h a r g e dr e gi o ni nI C L - 3o fG i-coupled D2-DR, and 5-HT1AR
[32, 94]. The replacement of the residues in Gαi1 subunit by
the corresponding residues in Gαs (Q304Ra n dE 208L) leads to
uncoupling mutant Gαi1 to D2-DR, whereas the replacement
of α4 helix residues in Gαs by the corresponding residues in
Gαi1 (R342Qa n dL 346E) induces, on the contrary, activation
of mutant Gαs by D2-DR. It was shown also that peptides
derived from N-ICL-3 of Gi-coupled D2-DR, 5-HT1ARa n d
α2B-AR give a 1.5–2.5-fold increase of GTP binding of the
wild type of Gαi1 but have no eﬀect on Gαi1 with paired
mutationQ304R/E208L.Atthesametime,havingnoinﬂuence
on the GDP/GTP exchange of the wild type of Gαs theyJournal of Amino Acids 11
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Figure 2: The intracellular regions of G protein-coupled receptor
of the serpentine type (yellow) participating in the interaction with
heterotrimeric G proteins.
signiﬁcantly increase GTP binding of the Gαs with mutation
R342Q/L346E[ 32]. The fact that all Gαi/o, unlike the other
typesofGαsubunits,haveananionicclusterintheα4helic es
gives grounds to suggest that positively charged intracellular
regions of Gi/o-coupled GPCRs interact with two anionic
regions of Gαi/o, the C-terminus and the α4 helix, while
the same regions of Gs-a n dG q/11-coupled GPCRs only
with the C-terminus. Thus, the extreme C-terminus, the α4
helix and the α4/β6l o o po fG α subunit are responsible for
its selective interaction with receptor and account for the
ability of synthetic peptides corresponding to these regions
to inﬂuence signal transduction via the cognate Gα subunit.
Among the peptides derived from C-terminal region of
the Gα subunits the best studied is the peptide 340–350 of
transducin Gαt subunit [135, 136]( Table 1). This peptide
binds with photoactivated rhodopsin, meta-II-rhodopsin,
and stabilizes the active signaling meta-II-rhodopsin con-
formation, thus mimicking the eﬀects of transducin [73,
75]. Peptide 340–350 also interacts with meta-Ib-rhodopsin,
another intermediate of light-activated receptor, forming a
complex with inactive GDP-bound transducin, and with
active G-protein-binding state of opsin, the ligand-free form
of rhodopsin, stabilized at low pH [74, 76].
The peptide interacts with the inner segments of TM5,
TM6, TM7, and the N-terminus of the additional helix 8 of
active forms of opsin [137–139]. The interaction between
peptide 340–350 with Lys341 replaced by leucine and the
inner surface of TMC of rhodopsin leads to destruction of
a hydrogen bond network which includes the side chains
of Arg135 and Glu134 from the conserved E(D)RY motif
localized in TM3/ICL2interfaceandthe side chains ofGlu247
andThr251 localizedincytoplasmicendofTM6.Theseevents
provoke the outward movement of TM6 and the formation
of TM5–TM6 pair is stabilized by new interactions between
the side chains of Glu247 and Thr251 of the TM6 that are
released from Arg135 and the side chain of Lys231 of the
TM5. The peptide binding to rhodopsin is supposed to be
rate-limited by the outward movement of TM6 [135]. The
contacts with inner surface of the TM5 and TM6 induce a
α-helical conformation in peptide 340–350(K341L) with a C-
terminal reverse turn. The carbonyl groups in the reverse
turn constitute the centre of a hydrogen-bonded network,
which links the two receptor regions containing the E(D)RY
motif and the conserved NPxxY(x)5,6F motif connecting the
TM7 and the helix 8.
The analogs of C-terminal peptide 340–350(K341L) can
stabilize meta-II-rhodopsin when they are covalently bound
to one of the two native reactive cysteine residues, Cys140 and
Cys316, localized on the intracellular surface of rhodopsin.
Using synthetic peptides that diﬀer in localization of a
chemical crosslinking group, either at the N-terminus or the
C-terminus of peptide 340–350(K341L), it was shown that
the N-terminus of peptide analog M-23S is crosslinked to
Cys140 and the C-terminus of peptide analog B23S-IA to
Cys316 [75]. The peptide M-23S crosslinking to the Cys140
localized on the cytoplasmic tip of TM3 and the peptide
B23S-IA crosslinking to Cys316 localized in N-terminus of
helix 8 are both necessary for stabilization of meta-II-
rhodopsin. At the same time, peptide B23S-IA stabilizes the
more compact meta-IIa-rhodopsin whereas peptide M-23S
stabilizes meta-IIb-rhodopsin, protonation form of meta-II-
rhodopsin capable of activating the G protein [75].
Using IR-spectroscopy it was shown that negatively
charged residues in the peptide 340–350 have a very impor-
tant role in its interaction with rhodopsin [140]. Free car-
boxylgroupsofGlu342 andAsp346 residuesinGαt C-terminal
peptidesubunitparticipateinspeciﬁcbindingwithpositively
charged intracellular regions of rhodopsin. The elimination
of the N-terminal positively charged amino group by N-
acylation of peptide 340–350 and delocalization of its
positive charge replacing lysines by arginines increase the
aﬃnity of modiﬁed peptide for meta-II-rhodopsin, whereas
amidation of the C-terminal negatively charged carboxyl
group, on the contrary, reduces it [141]. The substitution
of positively charged lysine by uncharged leucine greatly
increases the aﬃnity of peptide 340–350(K341L), designated
as23S,formeta-II-rhodopsinandstabilizesitsconformation
[142]. Highly conservative in Gαt and Gαi/o subunits Cys347
residue, the target for ADP-ribosylation by PT, is involved
in a hydrophobic interaction between peptide and meta-II-
rhodopsin, since with the substitution of this cysteine by
amino butyric acid, where the methylene-sulfhydryl group
is replaced by an ethyl group the activity of the C-terminal
peptideismaintained,whereassubstitutionbyalaninegivesa
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of the peptide. Alongside with this, the modiﬁcation of
cysteine SH-group by ribosyl radical brings about changes
in the conformation of C-terminal region in full-size Gαt
subunit as well as of peptide 340–350, which disturbs their
interaction with rhodopsin.
Itwasshownthatpeptides,derivativesofC-terminalsites
of the Gαs,v e ryd i ﬀerent in length disturb by the competitive
mechanism the functional interaction of receptors and Gs
proteins and change the aﬃnity of receptors for hormones
[66, 77, 143–151]. The expression of 83-mer polypeptide
derived from C-terminal region of the Gαs induces the inhi-
bitionofβ2-AR-andD1A-DR-mediatedcAMPproductionin
HEK293 cells [146]. Short synthetic peptides corresponding
toprogressivelylongersegmentsoftheGαs C-terminus,384–
394, 382–394, 380–394, 378–394(C379A), 376–394(C379A),
and 374–394(C379A), stimulate speciﬁc binding of selective
agonistCGS21680totheGs-coupledA2A-adenosinereceptor
in the rat striatal membranes both in the presence and in
the absence of GTPγS, a nonhydrolysable GTP analog, which
uncouples G proteins from receptors (Table 1). The most
eﬀective peptides are 378–394(C379A), 376–394(C379A), and
374–394(C379A), and the shortest peptide 384–394 is less
active [77]. In accordance with the results of the study of
Gαs crystal structure of the Gαs, the α5-helix responsible for
eﬀective interaction with the receptors involves the region
from Asp368 to Leu394 [152]. Thus, the peptide containing
17 and more amino acid residues have a stronger propensity
to assume an α-helical conformation compared with the
shortest peptides. The NMR analysis of 11-mer 384–394 and
21-mer 374–394(C379A) peptides was made and showed
that both peptides demonstrate a marked propensity to form
α-helical structure in hexaﬂuoroacetone/water, a mixture
with structure stabilizing properties, peptide 384–394 having
the shortest α-helix between Arg389 and Leu394, and peptide
374–394(C379A), the longest α-helix spanning region from
Asp381 to Leu394 [77, 153]. The addition of the most active
21-mer 374–394(C379A) peptide causes an increase of the
number of binding sites but does not stabilize the high-
aﬃnity state of the A2A-adenosine receptor. Peptide 374–
394(C379A) inhibits agonist-stimulated AC activity by 35%
and does not have a signiﬁcant eﬀect on the basal and
forskolin-stimulated activities. This is the evidence that the
peptide disrupts the signal transduction on the stage of
coupling between agonist-activated A2A-adenosine receptor
and Gs protein and does not interact directly with catalytic
unit of AC [77].
A 37-mer peptidic constrain (A42) containing a
16-mer membrane-permeable sequence (MPS) of pene-
tratin, derived from the homeodomain of the Drosophila
melanogaster transcription factor Antennapedia that translo-
cates through membranes, and a 21-mer peptide 374–
394(C379A) was designed and shown to have no aﬀect on
cell viability but to signiﬁcantly inhibit adenosine receptor-
mediated cAMP accumulation in PC12 cells with an EC50
of 5μM and decrease A2A-adenosine receptor- and β-AR-
mediated cAMP production in human cell line HMEC-1
[151]. The maximal eﬃcacy of NECA, a selective agonist
of A2A-adenosine receptor, is substantially reduced in the
presence of A42 peptide suggesting that it competes with
Gαs for the interaction with receptor. The A42 peptide
does not directly modulate AC activity and does not aﬀect
Gi-a n dG q-coupled receptor signaling, which indicates that
the speciﬁc target for peptide is the receptor Gs-binding
and -activating surface. Using NMR analysis it was shown
that A42 peptide is arranged in two stretches of α-helical
structure encompassing sequences 3–10 and 18–36. Even in
a membrane-mimicking environment and in conjugation
with MPS, the segment 18–36 has the secondary structure
resembling those of peptide 374–394(C379A) and of C-
terminal region in full-size Gαs [151]. The helix 18–36 is
amphipathic and has a polar surface lined by Asp378,A r g 390,
Asp381,a n dA r g 385 and two hydrophobic surfaces formed
by less polar residues Ile382,I l e 383,M e t 386,H i s 387,T y r 391,
and Leu393. The N-terminal penetratin fragment of A42
peptide also possessing α-helical structure has hydrophobic
and hydrophilic residues forming clustered surfaces at the N-
terminus and in the center of the fragment and is responsible
for peptide internalization by endocytosis.
The peptide strategy can be used to study the functional
roleofdistinct aminoacidresiduesintheC-terminus ofGαs.
The leucine residue localized at position (−2) is absolutely
invariant in C-terminal regions of all Gα subunits. The
substitution of this leucine (Leu393)w i t hA l a ,P h e ,L y s ,a n d
D-Leu in C-terminal peptide 384–394 from the Gαs C-
terminus gives modiﬁed peptides possessing much lower
activity compared with unmodiﬁed peptide [147]. However,
the peptides in which Leu393 was replaced by Asp and Thr
retain a residual activity. The conformational analysis of
peptides indicates that the side chain of Leu393, together with
side chains of Ile382 and Met386, is involved in formation of
a hydrophobic surface that is very important for eﬀective
interaction with the cognate receptor.
Minigene plasmids encoding 11-mer peptides corre-
sponding to the C-terminal regions of Gαi,G αo,G αq,G α12,
and Gα13 have been successfully used to discern the contri-
bution of diﬀerent types of G proteins to signal transduction
via m2-MChR and thrombin receptors [154–156]. Plasmid
minigene vectors encoding the C-terminal sequence of Gα
serve as competitive inhibitors presumably by blocking the
G protein-binding site on the GPCR that normally binds
the G protein. A minigene vector expressing the Gαi1/2 C-
terminal peptide speciﬁcally inhibits Gi1/2 protein inwardly
rectifying K+ channel activity following agonist stimulation
ofthem2-MChRanddecreasesthrombin-inducedinhibition
of AC activity in endothelial cells [154, 155]. The minigene
vectors expressing the Gαo and Gαq C-terminal peptides in a
competitive manner block the coupling between Go and Gq
proteins and the human thromboxane A2 receptor (TXA2R);
they signiﬁcantly decrease thrombin-stimulated intracellular
Ca2+ level and inhibit the stimulatory eﬀects of thrombin on
PLC activity; as a result PI 1,4,5-P3 production is blocked
[155, 156]. The minigenes encoding the C-terminal peptides
of G12 and G13 proteins decrease thrombin-stimulated stress
ﬁber formation that is mediated via G12/13 protein family
[155]. A minigene encoding mutated C-terminal sequence
of Gq protein, in which two C-terminal residues, Ala and
Val, are replaced by the Thr and Lys, has a little eﬀect on
thrombin-induced PLC activity, and even partially restoresJournal of Amino Acids 13
the response of the enzyme decreased in the presence of wild
Gαq C-terminal peptide [155]. A minigene expressing 15-
mer peptide of Gαq C-terminal region, the same as 11-mer
peptide, inhibits thrombin-stimulated PLC activity, and, in
addition, speciﬁcally binds to ligand-free TXA2R with high
aﬃnity (Kd is 17μM) and to agonist-activated receptor with
low aﬃnity (Kd is 240μM) [157]. It is a clear indication
that the C-terminal region of Gαq binds to TXA2R without
agonist, which suggests the existence of a preoccupied G
protein-binding site on the intracellular domains of ligand-
free TXA2R. The action of minigenes is very speciﬁc, being
realized that provided hormonal responses are mediated via
their cognate G proteins. The above is the evidence that the
useofminigene-basedpeptidestrategynotonlyconﬁrmsthe
view that each G protein can control certain signaling events
butalsoemphasizes,inaddition, thespeciﬁcityoftheGPCR-
G protein interface. Thus, the minigenes encoding Gα C-
terminal regions appear to be a powerful tool for dissecting
out the G protein that mediates a given physiological
function following thrombin activation.
As mentioned above for Gαs-derived A42 peptidic
constrain containing the MPS, the eﬃciency of Gα C-
terminal peptides depends on the ability of the latter to
penetrate the plasma membrane. A shorter peptide 350–359
corresponding to the extreme C terminus of Gαq modiﬁed
by MPS corresponding to Kaposi ﬁbroblast growth factor
signal region inhibits 5-HT2CR-mediated signaling in cul-
tured choroids plexus epithelial cells signiﬁcantly decreasing
serotonin-stimulated PLC activity, whereas its unmodiﬁed
membrane-impermeable analog is unable to disrupt the
functional coupling between agonist-activated 5-HT2CRa n d
Gq protein [145]. A peptide 385–394, derivative of the C
terminus of Gαs, modiﬁed by this MPS at the N-terminus
signiﬁcantly decreases, to almost basal level, β2-AR agonist-
induced stimulation of AC activity in astrocytes, whereas the
nonconjugated analog that is unable to penetrate the plasma
membrane has low inhibitory activity. It should be pointed
out that Kaposi ﬁbroblast growth factor-derived MPS alone
is inactive; therefore its contribution in the blockade of any
signal cascade tested is hardly of great importance. However,
it is not always the case. We showed that several polycationic
peptides used as MPSs can have inﬂuence on the activity of
the components of hormonal signaling systems, G proteins
and AC in particular, and their action must be taken into
account in developing cell-penetrating conjugates on the
basis of these peptides [51, 158–160].
The interaction of G proteins with the eﬀector enzymes,
AC in particular, is also very important for deciphering the
molecular mechanisms of GPCR-mediated signal transduc-
tion. Proceeding from the data that the crystal structure
of Gαs complexed with the soluble functional fragments
of AC shows three regions localized in Gαs, all having a
direct contact with the enzyme [161], three peptides 199–
216, 222–247, and 268–286 corresponding to these regions
were synthesized and their inﬂuence on the activity of the
types 2 and 6 ACs studied [78]( Table 1). An 18-mer peptide
199–216 encoding the Switch I region from Gαs stimulates
the basal and forskolin-stimulated activities of AC2 as well
as AC6, and forskolin does not appear to shift the peptide
concentration-eﬀect curves. This peptide also inhibits the
Gαs-stimulated activity of both isoforms of the enzymes
by about 30% and, thus, behaves as a partial agonist. At
the same time, the analogous peptide with the substitutions
G206P, I207D, E209K, and K211Ah a sn oe ﬀect on AC2 and
AC6 activities. The residue Ile207 of Gαs makes a contact
with AC while the residues Gly206,G l u 209,a n dL y s 211 are
responsible for appropriate local conformation of the Switch
I region. Peptide 222–247 encoding the Switch II region,
the same as peptide 199–216, stimulates the basal activity of
both AC isoforms making it 2-3 times higher, signiﬁcantly
increases forskolin-stimulated AC activity, and inhibits Gαs-
stimulated AC activity by 30–35%. Peptides 199–224 and
204–229 encoding the Switch II regions of the Gαi and Gαq,
respectively, that structurally are very similar to the Switch
II region of Gαs are not capable of stimulating the AC
activity [78]. The eﬀects of peptides 199–216 and 222–247
on the activity of AC2 are additive at lower concentrations
giving a left-shifted curve but are not additive at saturating
concentrations. A diﬀerent eﬀect is observed for AC6 where
peptide 222–247 lowers the eﬀect of peptide 199–224. In
the case of AC2 the stimulating eﬀect of peptide 199–224
is stronger compared with that of peptide 222–247 while in
the case of AC6 the eﬀect of peptide 222–247 predominates.
Now a suggestion can be put forward that the molecular
mechanisms underlying interaction of the Switch regions
of Gαs and AC isoforms are not all alike. Peptide 268–286
corresponding to α3-β5 region that interacts with the C-
terminal tail as well as with the central cytoplasmic loop of
AC inhibits the basal and forskolin-stimulated activities of
both enzymes by about 30% and, in addition, signiﬁcantly
decreases the Gαs-stimulated AC activity. Potent inhibition
of the Gαs-stimulated activity by peptide 268–286 indicates
that α3-β5 is involved in stabilization of the appropriate
orientation of the Switch regions required for eﬀective AC
activation. The peptide with the highly conservative residues
Trp277 and Trp280 replaced by Arg and Lys, respectively,
has no inﬂuence on AC activity [78]. Studying the Gαs-
derived peptides, speciﬁc functions of diﬀerent regions of
Gαs directly contacting AC were revealed.
6.AdenylylCyclases
Mammalian membrane-bound ACs producing the second
messenger cAMP in response to Gs protein stimulation are
represented by at least nine diﬀerent isoforms (AC1–AC9)
and possess two hydrophobic transmembrane regions, each
built up by six TM and two pseudosymmetric cytosolic
domains C1 and C2 that comprise subdomains Ca and
Cb. All AC subtypes are stimulated by GTP-bound Gαs
and diterpene forskolin, AC1 by Ca2+-calmodulin (CaM),
AC2 by Gβγ-dimer, while AC5, and AC6 are inhibited
by submicromolar concentrations of Ca2+ and AC1, AC5
a n dA C 6b yG T P - b o u n dG αi subunit. Synthetic peptides
are widely used for identiﬁcation of the regions in AC
cytoplasmic domains involved in the functional interaction
with the regulatory proteins and responsible for the enzyme
activity [79–81]( Table 1).14 Journal of Amino Acids
To determine the role of various interaction regions
within the C1 and C2 domains of the AC2 and AC6 in the
basal and Gαs-, forskolin- and Mn2+-stimulated activities,
ﬁve peptides corresponding to diﬀerent interface regions
involved in interaction with each other were synthesized
[81]. Two peptides, 427–444 and 487–511, correspond to α2-
β2-β3a n dβ4-β5-α4 regions of the C1 domain of AC6, and
three peptides, 899–926, 927–948, and 984–1015, to α2, β2-
β3, and α3-β4 regions of the C2 domain of AC2, respectively.
All these peptides inhibit both Gαs- and forskolin-stimulated
activities of full-length AC2 and AC6 expressed in Hi5 cells.
Peptides 487–511 and 984–1015 also inhibit basal activity
by 30%. Peptide 899–926 encoding C2 domain α2r e g i o n
inhibits the basal and Mn2+-stimulated activities of AC2
and AC6 by 52–59%, and Gαs- and forskolin-stimulated
activities of the enzymes by 55–63 and 71–80%, respectively.
T h eo t h e rp e p t i d e sd on o ta ﬀect Mn2+-stimulated activities
signiﬁcantly. The peptides with the replacement of residues
most important in the interaction with other amino acids
in the C1 and C2 domains, such as 427–444(R434D, K436D,
I437P), 487–511(G498P, K501E, Q503R), 899–926(E910K, R913P,
N916A, E917K, L926S), 927–948(K936D, I937F, K938D, T939F,
I940F), and 984–1015(H989D, F991K, N992K, K995G, I1010D,
G1011D, A1012Q, Q1013K) have no inﬂuence on the enzyme
activity. Thus, the peptide strategy suggests that the AC
activity stimulated by diﬀerent regulators involves distinct
interface interactions in the full-length enzyme, which indi-
cates that the AC may have multiple catalytically competent
conﬁgurations [81].
To identify CaM-binding regions in CaM-regulated
AC1 and to decipher the molecular mechanisms of CaM
regulatory action on the enzyme activity, the peptides
corresponding to C1b subdomain region 495–522 (pAC28)
of AC1 and C2a subdomain region 1024–1044 (pVLG) of
AC1 were synthesized [79, 80]. The peptide pAC28 exhibits
ah i g ha ﬃnity for CaM binding (Kd, 2nM) and inhibits
CaM-stimulated AC activity with IC50 equal to 500nM
[79]. The peptide pVLG binds CaM with low aﬃnity and
inhibits CaM-stimulated AC activity with IC50 equal to
10μM, which points to a minor role of the region 1024–1044
in CaM-mediated stimulation of AC1 activity compared
with the region 495–522. However, despite its rather high
aﬃnity for CaM, the peptide pAC28 binds to CaM in a
Ca2+-independent manner, although the modulation of AC1
activity by CaM is known to be very Ca2+-dependent. At
the same time, the peptide pVLG binds to CaM in a Ca2+-
dependent manner. These data speak in favor of the fact that
CaM requires not only Ca2+-independent C1b subdomain
region 495–522 but also Ca2+-dependent C2a subdomain
region 1024–1044 to stimulate AC1. When two CaM-critical
residues of the peptide pVLG, Val1027 and Leu1030,a r e
replacedbyalanines,thespeciﬁcbindingofmodiﬁedpeptide
pAAG with CaM is signiﬁcantly reduced and the peptide
pAAG competes with AC for CaM less eﬃciently than the
peptide pVLG, pointing to a sequence dependence of the
region 1024–1044 for binding to CaM. Thus, despite the
structural and functional variety and diﬀerent recognizing
motifs on AC, CaM, like Gαs and Gβγ subunits, and
forskolin, modulates the enzyme activity according to a
two-site-interaction mechanism [80]. The peptide pVLG,
in addition to inhibiting CaM-stimulated AC activity, also
decreasesthebasalactivityofAC1.ThepeptidepAAGhaving
the inactive amino acid substitutions is also able to inhibit
the enzyme activity. This is likely to be due to the interaction
of peptide 1024–1044 with complementary region forming
catalytic and/or regulatory sites of AC1 in CaM-free state.
7. The Familyof Phospholipases C
Inositol-speciﬁc PLCs are the family of Ca2+-dependent
multidomain enzymes, represented in mammalian cells by
several isoforms, such as PLCβ,P L C γ,P L C δ,P L C ε,P L C ζ,
and PLCη. They catalyze the hydrolysis of phosphatidyli-
nositol 4,5-diphosphate (PI 4,5-P2) to yield diacylglycerol
and phosphatidylinositol 1,4,5-triphosphate (PI 1,4,5-P3),
whichareimportantsecondarymessengers.PI1,4,5-P3 binds
to its receptor in the endoplasmic reticulum to open Ca2+
channels which increases the intracellular level of Ca2+
and activates calcium-sensitive enzymes, such as protein
kinase C (PKC) [162, 163]. The PLC activity is regulated
by many hormones and growth factors that realize their
eﬀects through GPCRs, receptor tyrosine kinases, and small
G-proteins of the Ras and Rho families. These enzymes
are implicated in intracellular signal transduction, vesicle
transport, endocytosis, exocytosis, regulation of the ionic
channels functions, mitosis, and cytoskeletal reorganization.
The family of PLCβ, the major eﬀectors of Gq proteins,
consists of four members diﬀerent in their response to G
proteins. The PLCβ1, for instance, is activated by GTP-
bound Gαq subunit and is insensitive to Gβγ dimer, and
the activity of PLCβ2, on the contrary, is regulated by Gβγ
dimer.ThePLCβ1isexpressedastwosplicevariants,PLCβ1a
and PLCβ1b, diﬀering only in the extreme C-terminal
sequences, 75 amino acid residues in PLCβ1a and 32 in
PLCβ1b. The PLCβ1a is localized in the cytoplasm, whereas
PLCβ1b is associated with the sarcolemmal membrane,
but deletion of the entire unique 31-mer sequence causes
cytosolic localization of mutant PLCβ1b. Using synthetic
peptides it was found that the critical role in association with
the membrane has a short 10-mer C-terminal segment of
PLCβ1b that determines functional activity of the enzyme
[82](Table 1).A myristoylated peptide corresponding tothis
segment of PLCβ1b enriched by proline residues induces the
dissociation of the enzyme from the sarcolemmal membrane
and inhibits its response to α1-AR agonists with EC50 of
12μM, whereas the same peptide from the C-terminus of
PLCβ1a taken as control is ineﬀective. Later it was shown
that a 32-mer C-terminal peptide of PLCβ1b competes
with full-size enzyme for sarcolemmal localization and
inhibits PLC activity stimulated by bsoth α1-AR agonist
norepinephrine and expressing constitutively active Gαq
[83]. A 32-mer PLCβ1b-peptide signiﬁcantly decreases a
substantial hypertrophic response induced by phenylephrine
and mutant Gαq subunit. So, PLCβ1b-peptides preventing
the enzyme association with the sarcolemma and inhibiting
signal transduction via Gq-coupled receptors downstream of
Gq activation may provide useful therapeutic agents for the
treatmentofhypertrophyandothercardiomyocytedamages.Journal of Amino Acids 15
The inhibition of hypertrophic signal transduction may be
also achieved using the peptides, derivatives of Gαq, that
a r ea b l et op r e v e n tp r e s s u r eo v e r l o a dh y p e r t r o p h ya n dt o
delay the progression of heart failure [164, 165]. However,
the inhibition of Gq-coupled signaling pathways involved in
control of fundamental cellular processes at the level of Gq
protein far from being an ideal strategy because it can induce
numerous dysfunctions in these pathways and, therefore, the
selective inhibition or stimulation of GPCR or the enzyme,
the generators of second messengers, PLCβ1i np a r t i c u l a r ,i s
preferable in this case.
The PLCβ-peptides are used for identiﬁcation of the
G protein-interacting regions in PLCβ [145, 166]. The
PLCβ1-peptide 1053–1084 modiﬁed at the N-terminus by
MPS corresponding to Kaposi ﬁbroblast growth factor
signal region in a dose-dependent manner inhibits GTPγS-
dependent activation of PLCβ1i nb o t hp u r i ﬁ e dP L C β1a n d
crude membrane preparations containing the intact enzyme,
which indicates the disruption of the functional interaction
between PLCβ1a n dG αq in active, GTP-bound, form [145].
Peptides 564–583 and 574–593 corresponding to the central
region of PLCβ2 speciﬁcally bind to Gβγ and inhibit
Gβγ-mediated stimulation of the enzyme activity [166].
Moreover, peptide 564–583 is more active compared with
peptide574–593,whichspeaksinfavorofthefactthatregion
564–583 contains all determinants required for eﬀective
Gβγ dimer binding. The modiﬁcation of peptide 564–583
with MPS does not inﬂuence their binding properties but
increases its ability to block Gβγ-mediated activation of the
enzyme activity in cultured cells [145].
The PLCβ-peptides are appropriate tools for identi-
ﬁcation of the enzyme isoforms participating in signal
transduction triggered by diﬀerent hormones that activate
Gq-a n dG i/o-coupled GPCRs [84, 145]. The PLCβ1-peptide
1053–1084 modiﬁed by MPS blocks, down to the basal
level, serotonin-induced phosphatidylinositol hydrolysis in
cultured choroids plexus epithelial cells, where Gq-coupled
5-HT2CR is the main mediator of serotonin stimulation.
The inhibitory eﬀect of peptide MPS-1053–1084 is dose-
dependent with IC50 equal to 55μM. The PLCβ2-peptide
MPS-564–583 does not signiﬁcantly inﬂuence 5-HT2CR-
mediated stimulation of phosphatidylinositol hydrolysis.
These data indicate that serotonin-induced activation of the
5-HT2CR leads to the release of active Gαq subunit and its
interaction with PLCβ1 speciﬁcally regulated by Gαq,b u t
not with PLCβ2 regulated by Gβγ dimer [145]. The same
happens in the case of metabotropic glutamate receptors
(mGluRs). At concentration 300μM peptide MPS-1053–
1084 signiﬁcantly inhibits phosphatidylinositol hydrolysis
stimulated by 3,5-dihydrophenylglycine, a speciﬁc agonist
of the types 1 and 5 mGluR (mGluR1 and mGluR5), in
primary cultures of astrocytes where Gq-coupled mGluR5
is expressed. In contrast, the treatment of the cells with
peptide MPS-564–583 does not decrease the stimulation
of mGluR-mediated phosphatidylinositol hydrolysis. These
data suggest that mGluR5-mediated signaling is involved in
PLCβ1a c t i v a t e db yG αq [145].
Microinjection of heptapeptide 1161–1167 correspond-
ing to the extreme C-terminal region of PLCβ3i nt h e
cytoplasm of the HN33 hippocampal cells leads to a
signiﬁcant decrease of calcium signaling induced by mGluR
agonist N-1,3-cyclopentanedicarboxylic acid [84]( Table 1).
Injection with the same C-terminal peptides of other PLCβ
isozymes, such as PLCβ1, PLCβ2, and PLCβ4, does not cause
any changes in the calcium signaling. As according to the
available data, the C-terminus of the PLCβ3 binds to adaptor
and regulatory proteins, a PDZ domain-containing mul-
timodular scaﬀolding protein Shank/ProSAP in particular,
mediating the interaction between ligand-activated mGluR,
Gq protein,andPLCβ3athighlyspecializedsubmembranous
sites, it can be assumed that peptide 1161–1167 competes
with the enzyme for binding with these proteins and, thus,
inhibits the transduction of a hormonal signal from the
receptor to the enzyme [84].
The membrane-permeable PLCβ-peptides, speciﬁcally
binding Gαq and Gβγ, can be used to study the involvement
of these subunits in PLC-independent signaling pathways
[145]. Pretreatment of HEK cells expressing the Gi/o-coupled
α2A-AR with PLCβ2-peptide MPS-564–583 that speciﬁcally
binds Gβγ dimer completely blocks the activation of MAPK
by epinephrine through α2A-AR, while the PLCβ1-peptide
MPS-1053–1084 speciﬁcally interacting with Gαq does not
aﬀect α2A-AR-mediated MAPK activation. Unlike this, pre-
treatment of HEK cells expressing the Gq-coupled thrombin
receptor with MPS-1053–1084 blocks the subsequent activa-
tion of PLCβ by thrombin receptor-activating peptide, but
peptide MPS-564–583 in this case is ineﬀective. These data
show that activation of MAPK cascade by α2A-AR agonists
is mediated through Gβγ subunits released from the Gi/o
proteins, while the PLCβ activation by thrombin receptor
agonists involves Gαq,b u tn o tG βγ, which coincides with the
data obtained using the other methods [145].
Studying synthetic peptides corresponding to diﬀerent
loci of PLCδ1, putative CaM-binding motif 473–493 of IQ
type (VQXXXKXXXXK) was identiﬁed in the X/Y linker
region of the enzyme that was not detected in the other PLC
isoforms [86]( Table 1). Peptide 473–493 in a competition
manner inhibits the binding of CaM with PLCδ1, but only in
two cases, either in the absence of or at low concentrations
of Ca2+. The binding of CaM to peptide 473–493 is, indeed,
inversely related to Ca2+ concentration, while the peptide
coprecipitatesPLCδ1irr especti v eo fC a 2+ concentration.The
incubation of PLCδ1 with 10–100μM of the peptide causes
a 22–53% reduction in the ability of PLCδ1t oc a t a l y z e
hydrolysis of PI 4,5-P2. The results obtained with peptide
473–493showthatCaMbindswithputativeIQmotiflocated
within the catalytic site of PLCδ1 and inhibits the enzyme
activity [86].
In Sertoli cells FSH induces an immediate Ca2+ inﬂux
viaa Gs/AC/cAMP-independent signaling pathway involving
PLCδ1 and tissue transglutaminase possessing GTP-binding
and GTPase activities and designated as Gαh [167]. The
myristoylated peptide corresponding to region 747–763 of
PLCδ1 in a competition manner inhibits the enzyme activity
acting on the stage of coupling between FSH-stimulated
Gαh protein and PLCδ1, while U73122, a speciﬁc nonpep-
tidic inhibitor of PLC, directly interacts with the enzyme
and blocks its translocation from cytosol to the plasma16 Journal of Amino Acids
membrane, which is necessary for PI 1,4,5-P3 production
(Table 1). The pretreatment of rat Sertoli cells with 0.1 and
1μM of the peptide leads to a 50 and 90% reduction of
FSH-induced intracellular PI 1,4,5-P3 generation and to
a 35 and 70% reduction of the FSH-evoked Ca2+ inﬂux,
which demonstrates a critical role of Gαh/PLCδ1/PI 1,4,5-
P3 pathway in the FSH-induced Ca2+ inﬂux in Sertoli cells
[87, 167]. The action of the peptide is pathway-speciﬁc, since
it does not interfere with FSH-induced activation of Gs/AC
signaling pathway leading to an increase of the intracellular
cAMP level.
The PLCγ participates in the signal cascades involving
tyrosine kinase receptors, that is, brain-derived neurotrophic
factor receptors and nerve growth factor receptors, and
nonreceptor tyrosine kinases, for example, B-cell recep-
tors and T-cell receptors, as the sensor components, and
scaﬀolding molecules, Bruton’s tyrosine kinase in particu-
lar, that mediate the functional coupling between ligand-
activated receptor proteins and PLCγ [168]. As is known,
the PLCγ contains adjacent to its SH2 and SH3 domains a
PLC inhibitor (PCI) region, including a positively charged
segment YRKMRLRY, that strongly suppresses PI 4,5-P2
hydrolyzing activity. Synthetic peptides identical to the PCI
region inhibit theenzyme activity inducednot only by PLCγ,
but also by PLCβ and PLC-δ [169]. In addition, they inhibit
Ca2+-dependent PLC activation in digitonin-permeabilized
cells and agonist- and GTPγS-dependent PLC activation in
puriﬁed plasma membranes [170]. The modiﬁcation of PCI-
peptide 724–736 by the conjugating myristic acid at the N-
terminus increases its PLC inhibitory eﬀects in vitro [85]
(Table 1). The Ki values are 120 and 3.5μM for unmodiﬁed
peptide 724–736 and its myristoylated analog, respectively.
Myristoylated peptide 724–736 at concentrations in the sub-
micromolarrangesigniﬁcantlysuppressesinvitroPI1,4,5-P3
formation induced by hormones and growth factors (EGF,
PDGF, bombesin) in Swiss 3T3 ﬁbroblasts (the IC50 values
areratherlow,approximately1μM)andstronglyinhibitscell
proliferation induced by these stimuli in vivo in erbB-, v-raf-
and B-raf-transformed NIH 3T3 cells, neutrophils, isolated
pancreaticcells,andSwiss3T3ﬁbroblasts.Thisindicatesthat
myristoylation of PCI-peptides leads to structural alteration,
resulting in their eﬀective entry into substrate-containing
vesiclesandcloseassociationwithPLC.Theinhibitoryeﬀects
on the basal PLC activity and hormone-stimulated PI 1,4,5-
P3 formation and proliferation of N-myristoylated peptide
724–736 with the replacement of the Tyr726 and Tyr734 by
phenylalanines are much less potent than the eﬀects of the
original myristoylated peptide. This gives grounds to say
that biological activity of PCI-peptides depends to a large
extent on tyrosine residues [85]. There is one thing to be
mentioned at this point that unmodiﬁed peptide 724–736
with the Y726F/Y734F replacement is not active at all.
8. Phosphatidylinositol 3-Kinase
Heterodimeric PI3-K consisting of regulatory p85 and
catalytic p110 subunits generates phosphoinositide second
messengers, such as phosphatidylinositol 3,4,5-triphosphate
(PI 3,4,5-P3) and phosphatidylinositol 3,4-diphosphate (PI
3,4-P2),andregulatesanarrayofsignalingpathwaysthrough
the membrane recruitment and activation of downstream
eﬀector proteins [171]. It was shown that C-terminal SH2
domain of PI3-K p85α subunit contains PI 3,4,5-P3-binding
region 18–29 and displays discriminative aﬃnity for this
phosphoinositide, depending on the length of acyl chain and
the charge density on the phosphoinositol ring of PI 3,4,5-
P3. Peptide 11–29 including the region selectively binds PI
3,4,5-P3 with Kd of 30μM, as in the case of the full-length
C-terminal SH2 domain, but has the binding aﬃnity for
other phosphoinositides, PI 3,4-P2 in particular, which is
one to two orders of magnitude lower compared with PI
3,4,5-P3 [88]( Table 1). This peptide in a dose-dependent
manner inhibits the binding of [3H]di-C8-PI 3,4,5-P3 to the
full-length C-terminal SH2 domain of PI3-K p85α subunit
immobilized onto streptavidin-coated beads with IC50 of
62μM. On the addition of PI 3,4,5-P3 the contribution of
α-helical conformation in the peptide structure increases
signiﬁcantly. Besides, conﬁrming the fact that the binding
site for PI 3,4,5-P3 is localized within region 11–29, these
ﬁndings suggest that the other regions of p85 subunit are not
involved in this binding [88].
9.ProteinKinaseC
The family of the PKCs, intracellular serine/threonine pro-
tein kinases, includes classical forms of the enzymes (PKCα,
PKCβ,a n dP K C γ) undergoing activation in the presence
of diacylglycerol and calcium ions, novel isoforms of PKC
(δ, ε, η, θ) independent of Ca2+ regulation, and atypical
PKC isoforms (ζ, ι) independent of diacylglycerol and Ca2+
[172]. All PKCs possess C-terminal serine/threonine protein
kinase domain linked to a regulatory domain including
an inhibitory region, designated as the pseudosubstrate
site [173]. As is known, PKCs are inactive in the absence
of activating agents owing to an intramolercular inter-
action between a short inhibitory sequence located in
the pseudosubstrate site and the substrate-binding region
of the catalytic domain. Synthetic peptides corresponding
to pseudosubstrate inhibitory sequence selectively decrease
functional activity of PKC [174, 175]. To penetrate into
cell pseudosubstrate peptides were subjected to modiﬁcation
using MPS derived from Antennapedia protein or HIV-
1 TAT protein and hydrophobic fatty acid radicals [89,
176, 177]. As a rule, such modiﬁcation has no inﬂuence
on cellular processes, neither does it change the spectrum
of inhibitory properties of pseudosubstrate peptides. How-
ever, cell-permeable pseudosubstrate peptides from PKCα/β,
PKCη,P K C ζ, and kinase domain of EGF receptor modiﬁed
by myristoyl radical, in addition to inhibiting PKC activity,
possess the ability to activate ERK1/2 and p38 MAPK, the
componentsofMAPKcascade,andtheintracellularenzymes
(AKT kinase, in particular) involved in endothelial nitric
oxide synthase activation and NO production [89, 178]
(Table 1). Because an increase of endothelial nitric oxide
synthaseactivityseemsbeneﬁcialinthecaseofmanydiseases
such as ischemic stroke, hypertension, and atherosclerosis,
PKC-derived myristoylated peptides have a good chance toJournal of Amino Acids 17
be used as pharmacological compounds for acute activation
of the enzyme.
10. The Molecular Mechanismsof
Action of Intracellular
SignalProtein-DerivedPeptides
According to the present view, there may be three molecular
mechanisms of action of signal protein-derived peptides, all
including diﬀerent models of the competition relationships
between the peptide and its cognate signal proteins.
Theﬁrstmechanismisbasedonthecompetitionbetween
the peptide and its cognate full-length signal protein for
the interaction with the other functionally and structurally
complementary signal and proteins, components of signal-
ing cascade. According to this mechanism, GPCR-peptide
directly interacts with G protein subunits, Gα or Gβγ;
Gα-peptide with the Gβγ-dimer complex, the receptor or
the enzyme generating the second messenger; AC-derived
peptidewithGproteinorAC-competentregulatoryproteins,
CaM in particular; and so on. This creates conditions
for GPCR-peptide corresponding to G protein-activating
region of the receptor to activate G proteins in a dose-
dependent manner and trigger coupled to them signaling
cascades and in a competition manner to disturb functional
interaction between its cognate ligand-activated receptor
and G proteins, decreasing or completely blocking the
signal transduction. Then GPCR-peptide will function as
antagonist of GPCR-signaling. A peptide corresponding to
the extreme C-terminal region of Gα subunit binds to G
protein-activating region of GPCR and selectively inhibits
the transduction of hormonal signal from ligand-activated
receptor to its cognate G proteins, acting also as antagonist
of signal transduction. The peptide, derivative of the C-
terminal region of the PLCβ3, competes with the full-size
enzyme for binding with adaptor and regulatory proteins,
including scaﬀolding protein Shank/ProSAP, which leads to
destabilization of functionally active receptor-Gq protein–
PLCβ3 complex and to inhibition of hormone-induced
stimulation of phosphoinositide hydrolysis [84].
The second mechanism includes the interaction of syn-
thetic peptide with complementary regions of protein
homologous to it. According to Covic and colleagues, this
mechanism accounts for the ability of pepducins to activate
or, contrary to this, to inhibit signal transduction via their
cognate receptor [97]. When pepducin acts as agonist, it
binds to the high-aﬃnity activating site formed by the intra-
cellular regions of GPCR and, thus, stabilizes or induces the
active state of receptor, which makes it possible for the latter
to interact eﬀectively with G proteins and trigger signaling
cascade.When pepducin acts as antagonist, it binds to lower-
aﬃnity inhibiting site that blocks the interaction between
ligand-activated receptor and G protein and prevents the
transduction of signal to G protein. According to this two-
site mechanism, GPCR-peptide speciﬁcally interacts with
complementary regions of its cognate receptor that in intact
receptor have contacts with the region homologous to the
peptide aﬀecting their mobility and rearrangement. The
peptides corresponding to various regions within the C1 and
C2 domains of the AC2 and AC6 diﬀer in the ability to
inﬂuencethebasalandforskolin-,Gαs-andMn 2+-stimulated
activities, which indicates that these peptides interact with
diﬀerent complementary regions forming catalytic and regu-
latory site of the enzyme.
The data obtained in our and the other authors’ investi-
gations show that the receptor speciﬁcity of GPCR-peptides
and the dependence of their action on the receptors homolo-
gous to them unambiguously speak in favor of the second
mechanism of action of GPCR-peptides [26, 39, 50, 97].
The receptor speciﬁcity and the need in cognate receptor
are likely to be both responsible for participation of the
cognatereceptorinrealizationofregulatoryeﬀectsofGPCR-
peptides, which resembles the action of signal protein-
derived peptides carried out by the second mechanism.
Thedataabouthighreceptorspeciﬁcityofpepducins,the
lipidated GPCR-peptides, are mentioned before. Studying
5-HTR-derived peptides we found that they aﬀect only
their cognate 5-HTR and practically do no inﬂuence the
activity of structurally close to them 5-HTRs [39]. 5-HT6R-
peptide 258–268 reduces the stimulating eﬀects of serotonin
and, to a greater extent, EMD-386088, a selective 5-HT6R
agonist, on AC activity and Gs proteins GTP binding. At
the same time, the agonists of the other types of 5-HTR,
which are also able to stimulate AC system, still have such
eﬀects.Theinhibitoryeﬀectofpeptide258–268onserotonin
signaling is blocked in the presence of 5-HT6R antagonists
SB-271046 and methiothepin but is retained in the presence
of antagonists of the other types of 5-HTR. 5-HT1BR-peptide
300–316 decreases AC inhibiting eﬀects of serotonin and 5-
HT1R agonists, especially of selective 5-HT1BR agonist 5-
nonyloxytryptamine, and their stimulating eﬀects on the Gi
proteins, while the eﬀects of agonists of the other types of 5-
HTR in the presence of this peptide do not change. 5-HT1BR
antagonists reduce or completely block the eﬀects of peptide
300–316, whereas the antagonists of the other types of 5-
HTR in this case are not eﬀective [39].
As mentioned above, the action of P1pal-19 corre-
sponding to N-ICL3 of PAR1 on PLCβ and the other
downstream eﬀector enzymes is partially or completely
blocked in cultured cells and tissues where the cognate PAR1
is absent. Peptide P1pal-19 and its analogs are ineﬀective in
the presence of the mutant PAR1 entirely devoid of CTD. It
follows that activation of the G proteins by P1pal-19 requires
the presence of the CTD of the receptor and it may provide a
binding site for PAR1-derived pepducins [98]. Peptide 615–
629derivedfromrelaxinreceptorRXFP1stimulatesthebasal
AC activity in the rat myocardium and brain with abundant
RXFP1 receptors, but it does not aﬀect the enzyme activity
in the skeletal muscles [50], where relaxin regulates AC via
the receptor of a diﬀerent type [179]. The action of 5-HTR-
peptides on AC system is well expressed in the brain, the
main target of serotonin, and rather little in the muscle and
reproductive tissues, where the 5-HTRs are expressed weakly
or not at all [39].
The third mechanism of action of signal protein-derived
peptides is based on their ability to inﬂuence the stability of
homo- and heteromeric complexes formed by their cognate18 Journal of Amino Acids
proteins, which in many cases accounts for the functional
activity of these proteins. It is shown that the cyclic peptide
225–273 constructed on the basis of a full-size ICL3 of
the V2-vasopressin receptor induces a signiﬁcant inhibition
of the bioluminescence resonance energy-transfer signal
between constrains V2 receptor-luciferase and V2 receptor-
yellowﬂuorescentprotein,indicatingthatitmodiﬁesthedis-
tance and/or orientation between these constrains engaged
in formation of dimeric complex and, thus, causes a dose-
dependent decrease in speciﬁc binding of [Arg8]-vasopressin
as a result of transition of the receptor high-aﬃnity to low-
aﬃnity state and inhibits vasopressin-induced stimulation
of AC activity [55]. Peptide 260–276 corresponding to C-
ICL3 of D2-DR also aﬀects the stability of the heterodimeric
complex between D1-a n dD 2-DR, which leads to alteration
of dopamine signaling in the brain [32, 40, 42]. There is a
view that peptide competes with its corresponding region
in intact D2-DR containing a positively charged segment
RRRRKR217−222 for binding to the anionic site located in
CTD of D1-DR and prevents the D1/D2-heterodimerization.
So, GPCR-peptides change the stability of receptor com-
plex and are capable of acting either as positive allosteric
regulators inducing the appropriate cellular response to
agonist even at a very low concentration or as negative
allosteric regulators blocking partially or completely this
response.
Concerning the mechanism of action of signal protein-
derived peptides realized in the cell, it is likely be a combina-
tion of the above mechanisms, depending on the structure
of the peptide and localization of the region homologous
to it in cognate protein, the modiﬁcation of peptides by
hydrophobic radicals and functional groups, the ability of
signal proteins to form intermolecular complex, and other
things. Finally, the choice between the ﬁrst and the second
mechanisms has a direct relation to the aﬃnity of peptide
for the proteins homologous to it or the proteins-partners
functionally interacting with the latter. If the aﬃnity of
synthetic peptide for complementary regions of the cognate
protein is higher than that for those of other proteins, the
preference is given to the second mechanism; if the aﬃnity
for complementary regions of other proteins speciﬁcally
interacting with the cognate protein is above that for the
latter, the ﬁrst mechanism comes into action, as a rule. The
aﬃnity depends not only on structural-functional features
of synthetic peptides and full-length signal proteins but also
on the physical-chemical properties of the medium (pH,
salts, polar and non-polar solvents, etc.), the presence of
hydrophobic surfaces, microenvironment of signal proteins,
and other factors.
11. Conclusion
Many approaches are used now to study hormonal signaling
systems and to develop speciﬁc and selective regulators
controlling their functional activity; the peptide strategy,
however, has some advantages compared to the others.
First, the length of biologically active signal protein-derived
peptidesdoesnotusuallyprecede15–20aminoacidresidues,
and they can be synthesized in a short time and in quantum
satis, using the solid-phase method, puriﬁed to homogene-
ity by reversed phase HPLC and characterized by mass-
spectrometry, amino acid analysis, and other appropriate
methods. Second, to enhance biological activity and selectiv-
ity of the action of peptides and to obtain their analogs with
higher stability to hydrolytic enzymes, signal protein-derived
peptides are subjected to diﬀerent modiﬁcations, such as
selective blocking of free functional groups of amino acids,
substitution of L- by D-amino acids and of natural amino
acids by rare, nonnatural, amino acids, synthesis of cyclic
and branched forms of peptides and their di- and oligomeric
constrains, and attachment to them of hydrophobic radicals.
Third, to obtain cell-penetrating forms of peptides, the latter
can be cross-linked either with the MPS represented by
short polycationic segment containing ﬁve or more arginine
residues, the amphiphilic helix having hydrophilic positively
charged side with lysine residues, often-applicable sequence
48–60 of HIV-1 TAT protein and signal sequence of Kaposi
ﬁbroblast growth factor, or modiﬁed by the hydrophobic
moiety such as hydrophobic TM helical segment, hydropho-
bic fatty acid, and steroid radicals mimicking TM of intact
signal protein. In the recent years in the synthesis of peptides
wide application has found the minigene approach, a new
biotechnology method in the frame of the peptide strategy.
This approach is very perspective for the synthesis of very
long peptides corresponding to full-length subdomains of
signal proteins as well as of chimeric constrains including
combination of regions derived from diﬀerent signal pro-
teins, but it is not applicable for obtaining modiﬁed by D-
and nonnatural amino acids, branched and oligomeric as
well as cell-penetrating forms of the signal protein-derived
peptides, and cannot be used with all cell types. At the same
time, a further modiﬁcation of the minigene approach with
the aim to expand its applicability must go on, especially
b e c a u s ei ta l l o w sc r e a t i o no faw h o l el i b r a r yo fs i g n a l -
protein-derived peptides for deciphering a complex network
of intracellular signal cascades and their selective regulation
andmodulation.Itisofspecialimportancethattheminigene
approach can be used to control the function of the central
nervous system, where small minigene-expressing peptides
mayserveasselectiveintracellularregulatorsandmodulators
of neuronal signal transmission.
It should be said in conclusion that on the addition to
peptides derived from signal proteins, the components of
hormone-sensitive signaling systems, some peptides gener-
ated from nonsignal proteins are also able to selectively regu-
late and modulate cell signaling, acting as a kind of bioactive
molecules within cells [180]. These peptides are released
in large amount by proteasomes and other extralysosomal
proteolytic systems and before complete degradation can
interfere with signal protein interaction, thereby aﬀecting
signal transduction, gene regulation, metabolism, protein
targeting, and apoptosis. In pathological conditions a change
in the composition of these intracellular nonsignal protein-
derived peptides can have inﬂuence on the activity of hor-
monal signaling systems, especially their downstream com-
ponents, and lead to disturbances in cell homeostasis.Journal of Amino Acids 19
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